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1 SUMMARY 
HCC is the most common type of cancer, often induced by viral infection with hepatitis B 
virus (HBV) or hepatitis C virus (HCV). Transforming growth factor-β (TGF-β) is an 
important cytokine upon liver damage as in wound healing and liver fibrosis due to its 
proapoptotic, antiproliferative and immunosuppressive functions on the epithelium. This 
work investigated the impact of HBV and HCV infection on TGF-β dependent signaling, 
its outcome and on the progression of chronic liver disease to HCC. 
cDNA microarrays were generated of primary human hepatocytes (PHHs) infected with 
HBV and treated with TGF-β for 1 and 24hrs, respectively. Gene expression analysis 
revealed that HBV regulated p53 and mTOR signaling pathway, the latter one known as 
being downstream of the Akt survival signaling pathway. Upon TGF-β treatment, HBV 
infection abrogated TGF-β signaling in PHHs and reduced the number of TGF-β 
regulated target genes. HepG2.2.15 cells, which replicate HBV, show decreased Smad3 
phosphorylation and transcriptional activity, and impaired TGF-β induced apoptosis. 
HBV replication increased Akt phosphorylation, but deactivation of Akt by its specific 
inhibitor LY294002 sensitized HepG2.2.15 cells for TGF-β induced apoptosis. This effect 
was Smad3 independent. TGF-β induced apoptosis upon Akt deactivation could be 
reduced by p38 MAPK inhibitor SB203580. 
To investigate the impact of HCV on TGF-β signaling, Huh7 cells were stably 
transfected with HCV core protein (Huh7-HCV core cells). In these cells, TGF-β 
dependent Smad3 phosphorylation and transcriptional activity were reduced, TGF-β 
induced apoptosis was abolished, and TGF-β target genes involved in cell cycle arrest, 
like GADD45β, p15, and p21 were downregulated. HCV core protein further induced 
expression of the pro-fibrotic cytokine connective tissue growth factor (CTGF), which 
was however TGF-β independent. 
In summary, the data of this thesis suggest, that HBV infection and HCV core protein 
interfere with canonical TGF-β signaling. Upon HBV infection, survival signaling 
pathways are induced, which counteract TGF-β signaling. Replication of HBV and 
overexpression of HCV core protein blunted Smad3 signaling and TGF-β induced 
apoptosis was abrogated. These results indicate that viral infection facilitates the escape 
of hepatocytes from the TGF-β induced apoptosis to assure viral survival in the 
hepatocytes. 
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2 
1 ZUSAMMENFASSUNG 
HCC ist eine der häufigsten Krebsarten, meist ausgelöst durch eine Infektion mit dem 
Hepatitis B Virus (HBV) oder Hepatitis C Virus (HCV). Aufgrund der proapoptotischen, 
antiproliferativen und immunsuppressiven Funktionen auf das Epithelium, ist 
Transforming Growth Factor-β (TGF-β) ein wichtiges Zytokin bei Leberschäden wie 
Wundheilung und Leberfibrose. Diese Arbeit untersuchte den Einfluß  einer HBV und 
HCV Infektion auf TGF-β abhängige Signalwege, deren zelluläre Effekte und 
Entwicklung von chronischer Lebererkrankung zum HCC. 
HBV infizierte primäre humane Hepatozyten (PHHs) wurden für eine, beziehungsweise 
24h, mit TGF-β behandelt und anschließend cDNA Mikroarrays generiert. Die 
Genexpressionsanalyse zeigte, dass HBV den p53 und mTOR Signalweg reguliert, 
letzterer wird über den Akt Survival Signalweg moduliert. Die Behandlung der HBV 
infizierten PHHs mit TGF-β zeigte, dass HBV die TGF-β Signalwirkung aufhob und die 
Anzahl der TGF-β regulierten Zielgene reduzierte. Die HBV replizierenden HepG2.2.15 
Zellen zeigten eine reduzierte Smad3 Phosphorylierung und transkriptionale Aktivität, 
sowie eine geminderte TGF-β induzierte Apoptose. Des Weiteren erhöhte die HBV 
Replikation die Akt Phosphorylierung. Durch Deaktivierung von Akt, mit dem Akt 
spezifischen Inhibitor LY294002, konnten HepG2.2.15 Zellen für TGF-β induzierte 
Apoptose sensibilisiert werden. Dieser Effekt war Smad3 unabhängig. Die TGF-β 
induzierte Apoptose aufgrund der Deaktivierung von Akt konnte wiederum durch den 
p38 MAPK Inhibitor SB203580 reduziert werden. 
Um den Einfluß von HCV auf TGF-β abhängige Signalwege zu untersuchen, wurden 
Huh7 Zellen mit dem HCV core Protein stabil transfiziert (Huh7-HCV core cells). Diese 
Zellen zeigten eine reduzierte TGF-β abhängige Smad3 Phosphorylierung und 
transkriptionale Aktivität. Des Weiteren war die TGF-β induzierte Apoptose aufgehoben, 
und TGF-β Zielgene, die im Zellzyklusarrest involviert sind, wie GADD45β, p15 und p21, 
waren herunterreguliert. Unabhängig von TGF-β induzierte das HCV core Protein die 
Expression des profibrotischen Zytokins Connective Tissue Growth Factor (CTGF). 
Zusammenfassend kann gesagt werden, dass die Ergebnisse dieser Arbeit darauf 
hindeuten, dass eine HBV Infektion und das HCV core Protein den kanonischen TGF-β 
Signalweg beeinträchtigen. Durch die HBV Infektion werden Überlebenssignalwege 
induziert, die dem TGF-β Signalweg entgegenwirken. Replikation von HBV und 
Überexpression des HCV core Proteins verminderten die Smad3 Signalleitung, sowie  
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die TGF-β induzierte Apoptose. Diese Ergebnisse weisen darauf hin, dass die virale 
Infektion Hepatozyten vor TGF-β induzierter Apoptose schützt, um das virale Überleben 
im Hepatozyten sicherzustellen. 
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2 INTRODUCTION 
2.1 HCC 
Hepatocellular carcinoma (HCC) belongs to the most frequent malignant tumors 
worldwide accounting for about 6% of all human cancers, with 564,000 new cases each 
year. Of liver cancers, HCC is the most common form, with a high mortality rate [1]. 
Etiologic factors associated with HCC are alcoholism, nonalcoholic steatohepatitis 
(NASH), aflatoxin B1 exposure and infection with Hepatitis B and C viruses (HBV/HCV), 
the latter two being responsible for 80% of HCCs [2]. However, HCC rate is much higher 
in low income countries, which is due to the higher incidence of HBV and HCV (Figure 
1). The development of HBV vaccination has highly reduced the rate of HBV-induced 
HCC. Further, improvements in early detection of HCC, like regular ultrasound 
examination and α-fetoprotein testing, have limited the impact of HCC [3]. The primary 
curative treatment is surgical resection; however, it is restricted to small tumors. Patients 
with large tumors (greater than Ø10cm) can only be treated with molecular targeted 
therapies [4]. Due to the different etiologic factors HCC is very heterogenic, making the 
development of a curative treatment difficult. Sorafenib is a multikinase inhibitor, 
inhibiting several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK 
cascade inhibitor. It induces apoptosis in neoplastic liver cells and attracted attention in 
treatment of HCC as it improved overall survival [5]. Interestingly, Ras/MAP kinase 
signaling was found to increase TGF-β expression and thus may be one explanation for 
the increased expression of TGF-β in HCC cells [6]. This was already investigated in 
1991 by Ito et al. who found elevated TGF-β expression in HCC tissue [7]. Under 
healthy conditions, TGF-β signaling functions as a tumor-suppressor that cancer cells 
have to bypass in order to proliferate. However, in malignant cells TGF-β signaling is 
also known to function as a tumor promoter, inducing migration/ invasion upon epithelial-
mesenchymal transition (EMT). The ability to switch TGF-β signaling from tumor-
suppressive to tumor-promotive, may account as survival and proliferation advantage for 
the tumor cells. Mechanisms explaining this often-observed phenomenon will be 
described in more detail below. 
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Figure 1: Liver cancer in the world (taken from [8]). 
 
2.2 TGF-β 
TGF-β is a multifunctional profibrotic cytokine, which exists in 3 isoforms. Isoform 1 has 
been described to be involved in pathogenesis of liver inflammation, fibrosis, cirrhosis, 
and HCC upon misregulation of its signaling pathway [9] [10]. As TGF-β1 has been 
found to be upregulated in many liver tumors [9] [11], it is thought to play a major role in 
at least a subset of cases displaying HBV- and HCV-induced carcinogenesis. 
Specifically, TGF-β controls cell proliferation, differentiation, apoptosis, migration, 
extracellular matrix remodeling, immune functions, and tumor invasion and metastasis 
[10]. Under healthy conditions, TGF-β1 secretion is restricted to Kupffer cells and is 
involved in liver homeostasis [12]. It is known as a growth factor for mesenchymal cells 
or as an inhibitor of proliferation of epithelial cells [13] [14]; for example, in fibrosis 
progression, TGF-β1 induces activation and proliferation of hepatic stellate cells (HSCs), 
whereas in "normal" hepatocytes, its outcome is cytostatic with provision of proliferation 
arrest and apoptosis [15]. TGF-β-induced growth inhibition and apoptosis is associated 
with its function as a tumor-suppressor. Interestingly, during the course of liver disease, 
hepatocytes become a major source of TGF-β with an autocrine effect. TGF-β1 
signaling may switch from being tumor-suppressive to tumor-promoting [16], triggering 
2 INTRODUCTION 
 
6 
proliferation, motility, invasion and metastasis (Figure 2). Thus, TGF-β signaling is also 
implicated in the process of epithelial mesenchymal transition (EMT), a significant 
feature of tumor progression [17], which was recently also discussed to be involved in 
earlier stages of CLD [18]. EMT is actually found during embryogenesis and wound 
healing responses in adults. However, EMT has been linked to cancer, as it allows 
epithelial cells to migrate and to invade surrounding tissue [19]. In vivo and in vitro 
studies have shown that TGF-β is involved in EMT [20] as it downregulates expression 
of epithelial markers like E-Cadherin, and ZO-1, and it upregulates mesenchymal 
markers like, vimentin, fibronectin, α-smooth muscle actin (α-SMA), or N-Cadherin [21]. 
Hence, TGF-β expression and its signaling pathway are thought to provide several 
advantages for tumor cells during cancer progression under certain circumstances [22]. 
Nevertheless, the specific conditions that induce the switch from cytostatic to 
tumorigenic for TGF-β have not been elucidated thoroughly yet. 
 
 
Figure 2: The role of TGF-β during the course of liver injury and regeneration towards 
hepatocarcinogenesis. TGF-β inhibits the proliferation during liver injury and regeneration. The switch of 
tumor-suppressive to tumor-promoting of TGF-β occurs during dysplastic nodules (DN) and early HCC. In 
advanced HCC cells TGF-β induces growth inhibition and EMT and contributes to tumor invasion through 
tumor-stromal interaction (taken from [23]). 
 
2.2.1 Canonical Smad-mediated TGF-β signal transduction 
The canonical TGF-β pathway is activated due to binding of bioactive TGF-β to its 
receptor type II (TβRII) (ALK5). This complex further interacts and activates TGF-β type 
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I receptor, forming a heterotetrameric complex. The receptor proteins Smad2 and 3 
become phosphorylated upon recruitment and interaction with TGF-β receptor type I 
(TβRI) serine and threonine residues. The activated Receptor (R)-Smad2 and 3 release 
from the receptor upon formation of a trimeric complex with the Common mediator (Co)-
Smad4, which is then able to translocate to the nucleus (Figure 3). By binding to 
promoters containing the minimal smad binding element (SBE) 5’-CAGAC-3’, the 
complex is able to activate or inhibit the expression of TGF-β target genes, like the 
upregulation of Plasminogen activator inhibitor-1 (PAI-I), procollagen I and III, CTGF, 
p15, p21, GADD45β or the repression of c-myc, Bcl-xL, HGF, and Id-1 [24] [25]. 
Although Smad2 and Smad3 are highly homologous, it has been shown, that there are 
functional differences between these two proteins. Yanagisawa et al. 1998 showed that 
overexpression of Smad3 in lung epithelial cells resulted in apoptosis upon TGF-β 
treatment, whereas Smad2 had not such a great impact [26]. Further, overexpression of 
dominant negative Smad3 in Hep3B cells inhibits TGF-β-induced apoptosis [27]. 
Recruitment of several different transcription factors, corepressors and coactivators 
further defines the signature of transcribed genes which is highly dependent on cell type 
and physiological context [28]. The expression of a specific set of transcription factors, 
corepressors and coactivators, might be one explanation how tumor cells can switch off 
the cytostatic, but not the tumor-promoting branch of TGF-β signaling. Furthermore, the 
different transcription factor complexes themselves are highly regulated by other 
signaling pathways, leading to crosstalk between TGF-β and other signaling pathways.  
Among the transcribed genes is the Inhibitory (I)-Smad Smad7, a negative feedback 
inhibitor of TGF-β signaling. One of its mechanisms to inhibit TGF-β signaling is by 
hindering Smad binding to the receptor and thereby their phosphorylation and activation. 
Further, Smad7 interferes with Smad-DNA complex formation in the nucleus [29]. 
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Figure 3: TGF-β signaling pathways. TGF-β signals through Smad and non-Smad pathways to regulate 
transcription of its target genes. TGF-β binds to TβRII to form an activated complex with TβRI, which is in 
turn able to c-terminally phosphorylate and activate Smad2 and 3. Both Smads form a trimeric complex 
with Smad4 and accumulate in the nucleus. Expression and repression of TGF-β target genes is 
performed in cooperation with transcription factors, corepressors and coactivators to regulate target gene 
expression. JNK and MAPK also phosphorylate Smads to influence their activation. Interaction of 
activated TβR complex with non-Smad signaling pathways including PI3K, Akt, p38, JNK, RhoA, and Erk 
can further influence gene transcription and cell fate. For detailed information see text (adapted from 
www.cellsignal.com; October 2012). 
 
2.2.2 Non-canonical TGF-β signaling and crosstalk 
Three different mechanisms have been defined leading to non-canonical TGF-β 
signaling. First, binding of TGF-β to the receptor complex results in the activation of 
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proteins from other signaling pathways, including GTPases Rac1, Cdc42, RhoA and 
Ras, the MAP kinases c-Jun N-terminal kinase (JNK), extracellular signal-regulated 
kinase (ERK), p38 MAP kinase, growth and survival promoting PI3K/AKT/TOR pathway, 
and tyrosine kinases FAK, Src and Abl [30] [31] (Figure 3). The phosphorylation of 
different proteins is mainly achieved by the dual specificity of the receptors acting as 
tyrosine and serine/threonine kinase which results in the recruitment of several adaptor 
proteins [32]. For example, p38 MAPK activation can be mediated via Src in breast 
cancer cells. Src phosphorylates TβRII, thereby recruiting growth factor receptor binding 
protein 2 (Grb2) and Src homology domain 2-containing protein (Shc) which are 
associated with adapter proteins responsible for p38 MAPK activation promoting 
oncogenic signaling by TGF-β [33]. Bhowmick et al. 2001 reported that in NMuMG cells 
activation of RhoA-dependent signaling by TGF-β induces stress fiber formation and 
mesenchymal-/ EMT-like characteristics [34]. Second, non-Smad signaling pathways 
can lead to phosphorylation and activation of Smad proteins. For example, in epithelial 
R-1B/L17 cells it was found, that ERK pathway can trigger direct phosphorylation of R-
Smads in their linker region, which impairs their nuclear translocation [35]. JNK 
phosphorylates Jun in COS-7, HepG2, and Mv1Lu cells, resulting in a complex 
formation of Smad2 and its corepressor protein TGIF leading to inhibition of Smad2-
dependent transcription [36]. Third, activated Smad proteins can activate or interact with 
proteins from other signaling pathways. Interestingly, Smads have been implicated in 
the posttranscriptional processing of microRNAs (miRNA), which participate in the 
regulation of messengerRNA (mRNA). Smads bind to the DROSHA microprocessor 
subunit p68 to facilitate processing of primary miR-21 (pri-miR-21) into precursor miR-21 
(pre-miR-21) thereby leading to an increased expression of miR-21 [37]. Imoto et al. 
reported in 2003 that Smad7 interacts with PIASy, a protein inhibitor of activated STAT 
in Hep3B cells [38]. In summary, non-canonical TGF-β signaling is highly complex and 
diverse, and many of its interactions are still not set in any context. However, it is 
probable that these interactions may contribute to the cancer-related effects of TGF-β 
signaling in a Smad-dependent or Smad-independent manner [39] [30]. 
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2.2.3 TGF-β-induced apoptosis and growth inhibition 
TGF-β-induced apoptosis and growth inhibition play a central role in liver tissue 
development and homeostasis. Due to the several different mechanisms of Smad-
dependent or independent TGF-β signaling, TGF-β-induced apoptosis and/ or growth 
inhibition can be mediated via different mechanisms depending on cell type and context. 
Upon canonical Smad signaling several transcribed genes are responsible for TGF-β-
induced apoptosis/ growth inhibition, e.g. phospholipid phosphatase SHIP [40], death-
associated protein kinase (DAPK) [41], TGF-β-inducible early response gene 1 (TIEG1) 
[42], and pro-apoptotic protein BIM [43]. Induction of cyclin-dependent kinase inhibitors 
(CDKIs) like p21 and p15 lead to inhibition of cell cycle progression in the G1 phase [44] 
[45]. TGF-β also represses the transcription factor c-myc, which is responsible for cell 
proliferation [46], and decreases the levels of anti-apoptotic Bcl-xL [47]. Smad-dependent 
expression of growth arrest and DNA-damage-inducible, beta (GADD45β) does not only 
lead to activation of apoptosis but also to a delayed activation of p38 MAP kinase 
pathways. In pancreatic carcinoma cells, this in turn leads to expression of 
thrombospondin-1 (TSP-1), which is involved in suppression of tumor cell growth and 
angiogenesis [48]. Another mechanism of TGF-β-induced apoptosis is mediated by 
MAPKs, like JNK and p38. The Daxx-JNK pathway mediates TGF-β-induced apoptosis 
upon binding of Daxx to TβRII. Homeodomain-interacting protein kinase 2 (HIPK2) 
phosphorylates Daxx which leads to the activation of MAP kinases MKK4/7 which then 
activate JNK, triggering apoptosis in AML12 hepatocytes [49] [50]. Yamashita et al. 
2008 reported that in HEK 293T cells TRAF6 becomes activated upon constitutively 
binding to TβRI and subsequent formation of the TβRI-TβRII-complex. This in turn 
activates the MAP kinase kinase kinase TAK1 in addition with recruitment of TAB2. 
Activated TAK1 then phosphorylates and activates MKK3 or MKK6, leading to activation 
of p38, whereby Smad7 functions as a scaffold protein facilitating this pathway. 
Furthermore, this signal transduction is independent of R-Smads and the kinase activity 
of TβRI. Hence, TβRI is able to activate either the canonical Smad pathway, or the 
pathway TRAF6-TAK1-p38/JNK [51] [52]. However, in Hep3B cells, Chen et al. 1998 
reported that the survival pathway PI3K/ Akt is able to protect against TGF-β-induced 
apoptosis upon blocking TGF-β-induced activation of caspase-3 without affecting Smad 
phosphorylation and nuclear translocation [53]. In 2004, Conery et al. showed, that TGF-
β-induced apoptosis is also dependent on the crosstalk with Akt/PKB serine/threonine 
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kinase in Hep3B cells. Akt is able to interact with unphosphorylated Smad3 in the 
cytoplasm, preventing its phosphorylation and translocation to the nucleus. Hence 
Smad3-dependent gene transcription important for TGF-β-induced apoptosis is 
inhibited. Interestingly, the interaction of Smad3 and Akt is independent of Akt kinase 
activity, but dependent on the ratio of Smad3 to Akt [54] [55]. Contrary, Song et al. 2006 
reported that Akt suppresses Smad3 activation in an Akt kinase-dependent manner by 
means of the downstream kinase mammalian target of rapamycin (mTOR) in a prostatic 
epithelial cell NRP-152 [56]. Seoane et al. 2004 described that Akt phosphorylates 
transcription factor FoxO, thereby inhibiting its nuclear translocation in neuroepithelial 
and glioblastoma cells. However, FoxO is needed for Smad3 transcriptional activity to 
induce p21 expression [57]. A lot of other groups had shown that Smad3 is the main 
driver responsible for TGF-β-induced apoptosis and growth inhibition. For example, Liu 
et al. 1997 reported that Smad3 phosphorylation and activation is required for TGF-β-
induced growth inhibition and transcriptional activation of the PAI-1 promoter in epithelial 
cells [58]. Wildey et al 2003 showed that Smad3 overexpression increases BIM 
expression and subsequently apoptosis upon TGF-β treatment in WEHI 231 B 
lymphocytes [59]. In summary, the induction of apoptosis and growth arrest by TGF-β is 
dependent on cell type and context, and the state of differentiation. However, there is no 
evidence that the different mechanisms are restricted to only a specific cell type or state 
of differentiation. Hence, this may explain the different outcomes upon TGF-β treatment 
of hepatocytes. 
 
2.3 HBV 
HBV has been discovered in 1970 as a member of the Hepadnavirus family [60]. Two 
billion people worldwide have been infected with the virus, of which more than 240 
million have chronic (long-term) liver infections, and about 600 000 people die every 
year due to the consequences of hepatitis B (WHO, July 2012). Although, most adults 
clear the infection spontaneously [61], a vaccination against HBV is available since 1982 
protecting for at least 20 years. Over one billion doses of hepatitis B vaccine have been 
used worldwide resulting in a significant reduction of HBV infection (WHO, July 2012). 
Unfortunately, vaccination and treatment therapies are barely available in developing 
countries and many people will still be infected. It is of major importance to elucidate the 
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underlying molecular mechanisms in more detail which lead to the development of HCC 
in chronic HBV infection [62]. Therapy treatment with antiviral drugs, like lamivudine, 
entecavir, or immune system modulators like pegylated interferon-alpha (IFN-α) cannot 
clear the viral infection, but can decrease viral replication [63]. Unfortunately, studies on 
HBV, its impact on cell transformation and the immune system, have been hampered, 
because HBV has a very strong tropism for liver parenchymal cells of humans, 
chimpanzees, woodchucks, or ducks. Since correlation of the immune system of 
woodchucks and ducks to the human immune system is not really reliable, and trials 
with chimpanzees are not always feasible, HBV is mostly investigated in cell culture 
models. Since HBV infection is restricted to differentiated cells, only PHHs can be 
infected, supporting HBV replication for several weeks [64] [65]. Some hepatoblastoma 
cell lines, like HepG2, do support HBV replication after transfection of HBV DNA, but 
impact on the host cell upon initiation of infection of HBV is not considered [66] [67]. 
However, Gripon et al. 2002 could develop the cell line HepaRG, which is susceptible to 
HBV infection, as they express several liver-specific receptors needed for viral entry 
[68]. 
 
2.3.1 HBV particle 
HBV is a small enveloped DNA virus (42nm Dane particle) with a relative small relaxed 
circular, partially double-stranded genome of around 3.2kb length with 4 overlapping 
open reading frames (ORF) (Figure 4). The pre-S/S ORF encodes the three viral surface 
proteins named large (L), middle (M) and small (S) surface protein. The pre-C/C ORF 
encodes the e antigen (HBeAg) and the core antigen (HBcAg). The P ORF encodes the 
terminal protein (TP) and the viral polymerase. The X gene encodes a small protein 
(HBx) that is essential for virus replication [69] [70]. HBV mutations, due to errors in viral 
reverse transcription, especially in the surface ORF, are important to escape the antiviral 
defense of the immune system. According to their genomic sequence variations, HBV 
has been divided into eight genotypes [71]. Further, based on antigenic epitopes 
presented on its envelope proteins HBV is also divided into four major serotypes (adr, 
adw, ayr, ayw) [72]. Interestingly, it has been argued that viral genotypes have different 
courses of HBV infection in terms of persistence, viral load, resistance to therapy, and 
HCC development [73]. Since HBV is a DNA virus, HBV DNA integration into the 
hepatocyte genome has been detected in around 80% of HCC from HBV-positive 
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patients [74] [75]. DNA integration is supposed to be a mechanism associated with HBV-
induced HCC development. Although this integration step is not obligatory and not 
necessary for viral replication, it allows persistence of the viral genome [76]. HBV DNA 
integration occurs often in genes encoding proteins crucial for cell proliferation and 
apoptosis [77]. Modification of its expression (e.g. cis-activation) with impact on 
carcinogenesis has been controversial [78]. Nevertheless, the HBx gene is the most 
commonly integrated and expressed protein found in HCC tissue [79]. Interaction of HBx 
with cellular proteins has also been reported. HBx has been investigated to interact with 
epidermal growth factor receptor, c-myc, c-jun, AP-1, SP-1, p53, and NFκB, among 
others [80]. These interactions may hold another mechanism of HBV-induced HCC 
development. 
 
 
Figure 4: The HBV viron is around 42nm in diameter. The envelope is a lipid bilayer containing viral 
surface proteins L, M, and S. The preS1 domain of the L protein can interact with cellular heat shock 
protein Hsp70. This is probably responsible for the dual function of preS1 domain in mediating contact 
between virus and host cell, and viral envelope and capsid [81]. The inner nucleocapsid consists of core 
protein and encloses the partially double-stranded circular DNA of around 3.2kb, of which the 5’-end of the 
complete (-)-DNA strand is covalently linked to the TP domain of P protein (taken from [69]). 
 
2.3.2 HBV and TGF-β 
Since TGF-β plays an important role in liver fibrosis [82], many studies have attempted 
to investigate the role of TGF-β in the course of HBV infection and whether it is usable 
as a marker in disease progression and severity. Flisiak et al. 2005 reported an 
upregulation of plasma TGF-β in acute viral hepatitis B, but not in hepatitis C. During the 
four-week follow-up TGF-β plasma levels decreased, although the levels were still 
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significantly higher than normal. Furthermore, they observed that the concentration of 
TGF-β at the beginning of the severe form of hepatitis B doubled in value from that of 
the mild form subgroup. Here as well, they could observe in the following weeks a 
decline in TGF-β levels of the severe form down to the concentrations found in the mild 
form subgroup. They state, that this higher release in TGF-β is due to more damaged 
hepatocytes during acute liver disease, but not due to its mechanism, and that this is 
different from chronic liver disease associated with the activation of hepatic stellate cells 
and fibrosis [83]. In line, Guo et al. 2009 showed that the HBx-expressing liver cell line 
QSG7701 grown in a co-culture system induced TGF-β expression in the hepatic 
stellate cell line LX-2 [84]. The group of Dong et al. 2008 investigated the levels of TGF-
β expression in livers, with respect to HBV replication, as determined by HBV DNA. In 
contrary to Flisiak et al, they reported, that hepatic TGF-β expression can be correlated 
with HBV replication and the degree of HCC differentiation [85]. In vitro studies by Yoo 
et al. 1996 showed, that HBx trans-activates the TGF-β promoter through the Egr-1 
binding sites in transfected HepG2 cells [86]. In line, Pan et al. 2004 could show in 
Mv1Lu cells stably expressing HBx higher TGF-β activity due to upregulation of TGF-β 
and downregulation of α2-macroglobulin [87]. Furthermore, TGF-β-sensitive Mv1Lu cells 
transfected with HBx were less responsive to TGF-β-induced apoptosis as determined 
by 3H thymidine incorporation [88]. In 2000, Shih et al could show that in TGF-β-
sensitive Hep3B cells stably expressing HBx, HBx was able to block TGF-β-induced 
apoptosis, but did not affect TGF-β-induced activation of the PAI-1 gene. Obviously, 
HBx is able to inhibit only the cytostatic branch of TGF-β signaling. Moreover, Akt 
phosphorylation levels were induced in HBx expressing cells. Deactivation of Akt by the 
inhibitor LY294002 could rescue TGF-β-induced apoptosis [89]. In contrary, Lee et al. 
2000, reported that HBx enhanced transcriptional activity upon TGF-β through direct 
interaction with Smad4 together with components of the basic transcriptional machinery 
[90]. 
In summary, it is still not clarified whether HBV infection results in an upregulation of 
TGF-β and the cellular source responsible for TGF-β release. There is incidence that 
HBx could inhibit tumor-suppressive functions of TGF-β, however, this not proven in 
regard to full HBV yet. 
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2.4 HCV 
HCV has been discovered in 1989 as a member of the Flaviviridae family [91]. Around 
3% of the worldwide population is infected by HCV, of which only a fraction is able to 
clear the virus spontaneously, whereas 80% become chronically infected [92]. 20% of 
chronically HCV-infected patients progress to cirrhosis and 1-3% will develop HCC [93]. 
Standard therapy treatment is a combination of pegylated IFN-α and ribavirin. 
Unfortunately, only 20% of patients are cured by this long-lasting and costly medication 
(approximately 35,000 $/ year). Furthermore this therapy is accompanied by severe side 
effects like, anemia, depression and flu-like symptoms [94]. However, new 
developments in therapy have been made recently. Bocepravir and telaprevir are direct 
antiviral drugs, which inhibit the NS3/4A proteases; both compounds progressed into 
phase III trials. Combination of both compounds together with standard therapy of 
peginterferon α and ribavirin increased sustained virologic response rates in treatment-
naïve genotype 1 patients from 38-44% to 66-75% [95]. 
 
2.4.1 HCV particle 
HCV is an RNA virus, with a genome of around 9,600kb. It is organized in one open 
reading frame encoding a 3,000aa polyprotein, which is cleaved into at least 10 proteins: 
the non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B are released from 
the precursor polyprotein upon cleavage by virus-encoded proteases and assist in viral 
replication and assembly. The structural proteins core, E1, E2, p7 are released from the 
precursor polyprotein upon cleavage by cellular proteases and compose the viral 
particle [96] (Figure 5). HCV is divided into 6 genotypes (1-6), which are further split into 
30 subtypes (1a, 1b, 3a...). Within the host, several quasispecies develop due to the 
high error rate of the RNA-Polymerase. This prolific and error-prone replication often 
leads to rapid emergence of point mutations that confer drug resistance [94] and allows 
the virus to escape from the host immune system and to establish a chronic infection 
(hcspFACTsheet, 2006). Interestingly, a switch from acute to chronic infection has been 
associated with a wider variety of quasi-species [97]. According to different tissue sub-
localizations, like tumor and non-tumor regions, different viral variants have been 
isolated suggesting that they may contribute to HCV-induced carcinogenesis [98] [99]. 
However, HCV is not able to integrate into the host genome. Nevertheless, it is assumed 
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that viral proteins like core, NS3, and NS5A interact with host proteins and cellular 
structures causing transformations due to oxidative stress, apoptosis, ER stress, and 
dysregulated signal transduction [100]. Since Lohmann et al. 1999 established an HCV 
subgenomic replicon system in a human hepatoma cell line, investigation of HCV 
replication, influence on cellular signaling pathways, and efficacy measurement of 
antiviral components was possible [101]. Recently, Bandaudha et al. were able to 
develop a culture system of primary human hepatocytes that support productive 
replication of infectious HCV genotypes 1a, 1b, and 2a [102]. These were striking news 
for the study of host response to HCV infection and progressive liver disease. Ever 
since, research groups especially focused on elucidating the rendered signaling 
pathways involved in HCV-induced HCC development, e.g. the Janus kinase (JAK), 
MAPK, tumor necrosis factor (TNF-α), sphingolipid, insulin, oxidative stress, and the 
TGF-β signal transduction pathway have been found to be influenced at least [92] [103]. 
 
 
Figure 5: Organization of the HCV genome. The viral RNA contains 3’- and 5’-untranslated regions (UTR) 
that are required for viral replication. The 5’-UTR also contains an internal ribosomal entry site (IRES) that 
directs translation of a viral polyprotein, which is further proteolytically processed into 3 structural and 7 
nonstructural proteins by viral enzymes (NS2/3 and NS3/4A) and cellular enzymes (signal peptidase and 
signal peptide peptidase) (taken from [104]). 
 
2.4.2 HCV and TGF-β 
Several publications showed that chronic inflammation as caused by HCV is 
accompanied by increased oxidative stress [105] [106] [107]. A role of reactive oxygen 
species (ROS) in carcinogenesis has been shown in many cases. Thus, ROS 
2 INTRODUCTION 
 
17 
downstream signaling components MAPKs, are reported to be involved in TGF-β/ Smad 
and integrin-mediated tumor metastasis [108]. Under healthy conditions, ROS are 
essential mediators of apoptosis involved in TGF-β-induced apoptosis. Interestingly, in 
Huh7 cells HCV induces TGF-β1 expression through a ROS-dependent activation of 
p38 MAPK, JNK, and ERK pathways [109]. In respect thereof, Wilson et al studied the 
effect of hypoxia inducible factor-1α (HIF-1α) in the lifecycle of HCV and hepatoma 
migration. They found an increase in HIF-1α expression in HepG2 cells expressing HCV 
glycoproteins and in Huh7.5 cells permissive for HCV infection, which resulted in higher 
cell migration and reduced cell polarity as assessed by enumerating MRP-2 positive 
BC/100 nuclei and tight junction integrity. The increase in HIF-1α led to an upregulation 
of the downstream effectors VEGF and TGF-β. Inhibiting either the VEGF or TGF-β of 
HIF-1α itself restored cell polarity and migration capacity, and additionally, had also a 
negative effect on HCV replication [110]. 
However, research using complete and infectious HCV virus is limited due to safety 
issues. Nevertheless, in order to further elucidate HCV impact on liver disease and HCC 
progression in more detail, several in vitro studies using individual viral proteins have 
been performed investigating their impact on cell behavior. Especially the HCV core 
protein attracted attention and was characterized to be involved in cell growth, apoptosis 
and carcinogenesis. Within the cell, it is often found on ER membranes, on the surface 
of lipid droplets, on the mitochondrial outer membrane, and to some extent in the 
nucleus [111] [112] [113]. Overexpression of HCV core protein in HepG2 cells resulted 
in enhanced cell proliferation concomitant with increased activity of JNK, Erk, and p38 
MAP kinases [114]. In regard to its effect on cell survival, core protein lead to secretion 
and autocrine stimulation of HB-EGF, thereby activating the Akt mediated anti-apoptotic 
pathway through Ras/PI3K signaling [115]. Several groups reported the influence of 
HCV core expression on the TGF-β-dependent cell cycle control, resulting in down-
regulation of cyclin-dependent kinase inhibitor p21 in HepG2 and in murine fibroblast 
NIH 3T3 cells, respectively. Mechanistic background of this inhibitory effect was later 
elucidated by Cheng et al, showing decreased DNA binding abilities of Smad3 due to 
interaction with HCV core protein (for more detail see below) [116] [117]. In line, Kwun 
and Jung published in 2003 that HCV core protein may regulate transcription of p21, 
depending on cell type and status in opposite manners. In HepG2 and Hep3B cells, p21 
is upregulated, whereas in primary hepatocytes and NIH3T3 cells, p21 is 
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downregulated. As possible mechanisms stabilization of p53 and balance between TGF-
β and sodium butyrate signaling pathways was suggested (the HCV core responsive 
region within the p21 promoter overlaps with the TGF-β/ Smad and the sodium butyrate 
responsive elements) [118]. The ability of HCV core to regulate transcription factors was 
also investigated. Shrivastava et al reported constitutive activation of Ap-1 by core, 
which correlated with the activation of JNK and MAPK [119]. Similarly, Cheng et al found 
that promoters containing Sp-1 or SBEs are not activated, while promoters which 
contain Ap-1-binding elements are [120]. Several investigations consistently found that 
overexpression of HCV core protein in hepatoma cells results in an upregulation of TGF-
β1 protein by activation of MAPK signaling pathways [121] [122] [123]. Although TGF-β1 
expression obviously is upregulated, its cytostatic/ proapoptotic signaling branch was 
often found to be abrogated. For example, Cheng et al investigated the TGF-β1 
signaling pathway in Huh7 cells and revealed that overexpressed HCV core protein may 
also directly interact with the MH1 domain of Smad3, thereby blocking TGF-β/ Smad3-
mediated transcriptional activation through interference with the DNA-binding ability of 
Smad3, but not with its nuclear translocation ability. These biochemical interactions lead 
to repression of TGF-β/Smad3-mediated apoptosis as investigated by TGF-β-induced 
p21 promoter activation. Further, overexpression of Smad3 increased the sensitivity of 
the Huh7 cells to TGF-β-induced apoptosis, whereas expression of dominant-negative-
Smad3 enhanced survival [120]. Pavio et al. in 2005 supported the direct impact of HCV 
core on TGF-β/ Smad3 signaling. They isolated Hepatitis C virus core variants from liver 
tumor but not from adjacent non-tumor tissue which interact with Smad3 and inhibit the 
TGF-β pathway in HepG2 cells [124]. In a follow-up study of the same group, Battaglia 
et al published that this liver cancer-derived HCV core protein switches TGF-β growth 
inhibitory effects to tumor-promoting responses in regard to components implicated in 
EMT by decreasing Smad3 activation [125]. Using an in vitro co-culture system with 
primary HSCs isolated from rats, and a stable HepG2-HCV core cell line which had 
been transfected with HCV core gene, HCV core protein promoted liver fibrogenesis via 
up-regulation of CTGF and TGF-β1 in HepG2 cells [122]. CTGF has been linked to 
TGF-β pathways in fibroproliferative diseases [24] [25]. Hence, Kovalenko et al. 
investigated the role of CTGF upregulation and its suitability for the assessment of liver 
fibrosis in HCV-infected patients. They could show that HCV infected patients had 
significantly higher serum CTGF levels than healthy controls and that CTGF correlated 
with the histological degree of liver fibrosis [126]. Another recent publication by Wu et al. 
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2012 on HCV-induced fibrosis investigated the effects of HCV core protein in a 
completely new experimental setup. They observed the impact of secreted HCV core 
protein on hepatic stellate cells and found increased expression of α-SMA, procollagen 
α2(1) and TGF-β [127]. 
In summary, HCV core protein has been associated to interact with Smad3 and to 
interfere with TGF-β induced apoptosis. In regard to this, there are still discrepancies, 
e.g. about the regulation of p21. Furthermore, it is not clarified yet, whether CTGF 
upregulation is dependent on TGF-β in this context. Most importantly, results obtained 
about HCV core protein, are still to be proven in a full HCV model. 
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2.5 Project aim 
Chronical HBV and HCV infection often lead to liver inflammation, fibrosis and finally to 
HCC. TGF-β is pivotal in liver cell signaling upon liver damage and during 
carcinogenesis TGF-β may turn from tumor suppressor to tumor promoter. The aim of 
this project was to elucidate the impact of viral infection on TGF-β dependent signaling 
pathway, signaling outcome and initial triggers for the progression of chronic liver 
disease to HCC. 
(i) HBV is able to cause HCC although it is a noncytopathic virus causing few gene 
aberrations. To elucidate the role of TGF-β signaling in the cause of HBV 
induced HCC, this study questioned whether HBV is able to change the 
outcome of TGF-β signaling from being a tumor suppressor towards being a 
tumor promoter. Therefore, cDNA microarrays were generated from freshly 
isolated primary human hepatocytes (PHHs) which were infected with HBV 
and treated with TGF-β in vitro. It was discriminated between early (1h) and 
late (24hrs) expression signatures and compared infected versus uninfected 
cells. To verify the microarray data results, HepG2.2.15 cells were analyzed 
for canonical TGF-β signaling, like Smad phosphorylation and transcriptional 
activation, and TGF-β induced apoptosis. 
(ii) HCV has been reported to negatively interfere with canonical TGF-β signaling, 
but the question whether TGF-β signaling changes from being a tumor 
suppressor towards a tumor promoter upon HCV has not been investigated in 
detail yet. The aim of this study was to verify functional effects of inhibition of 
TGF-β signaling like Smad phosphorylation and transcriptional activation, 
TGF-β induced apoptosis, and TGF-β induced EMT-like characteristics in 
transfected Huh7 cells, which overexpress HCV core protein, and in Huh7.5 
cells, which are highly permissive for full HCV replication. 
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 General technical equipment and devices 
Analytical balance Sartorius (Göttingen, Germany) 
Agarose gel electrophoresis system Bio-Rad Laboratories (Munich, Germany) 
Blotting chamber Invitrogen (Karlsruhe, Germany) 
Centrifuge for Eppendorf tubes Biofuge Eppendorf (Hamburg, Germany) 
Centrifuge Heraeus (Hanau, Germany) 
CO2 Incubator Kendro (Langenselbold, Germany) 
Confocal microscope Leica (Solms, Germany) 
Electrophoresis Powersupply Gibco BRL (Eggenstein, Germany) 
Geltray DNA gel Bio-Rad Laboratories (Munich, Germany) 
Gene Pulser system Bio-Rad Laboratories (Munich, Germany) 
Ice mashine Scotsman Ice Systems (IL, USA) 
Laminar Flow Heraeus (Hanau, Germany) 
Light microscope Leica (Solms, Germany) 
Luminometer Lumat LB9507 Berthold (Freiburg, Germany) 
Magnetic stirrer Heraeus (Hanau, Germany) 
Microlitre pipettes Eppendorf (Hamburg, Germany) 
Microwave Sharp (Hamburg, Germany) 
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Molecular Imaging System ChemiDoc Bio-Rad Laboratories (Munich, Germany) 
Microplate reader Tecan Tecan (Crailsheim, Germany) 
Neubauer hemacytometer Hecht (Sondheim, Germany) 
Pasteur pipettes WU (Bamberg, Germany) 
PCR mashine Bio-Rad Laboratories (Munich, Germany) 
pH electrode WTW (Weilheim, Germany) 
pH meter WTW (Weilheim, Germany) 
PipetBoy Integra Instruments (Hamburg, 
Germany) 
Real-time PCR Stratagene (Waldbronn, Germany) 
Refrigerator  Liebherr (Ochsenhausen, Germany) 
SDS-Page Mini Protean 3 Cell gel 
chambers 
Bio-Rad Laboratories (Munich, Germany) 
Thermomixer Eppendorf (Hamburg, Germany) 
Ultra low temperature freezer New Brunswick Scientific GmbH 
(Nürtingen, Germany) 
UV-Table iNTAS (Göttingen, Germany) 
Vacuum pump Vacuubrand GmbH & Co KG (Wertheim, 
Germany) 
Vortex  Heidolph (Kelheim, Germany) 
Water-purification system Milli-Q Millipore (Eschwege, Germany) 
Waterbath with termostat VWR (Bruchsal, Germany) 
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3.1.2 Disposable Material 
Blotting paper Whatman (Dassel, Germany) 
Cell Culture T-flasks (25, 75, 175 cm2) Greiner GmbH (Frickenhausen, 
Germany) 
Cover slides R.Langenbrinck (Teningen, Germany) 
Cryotubes Greiner GmbH (Frickenhausen, 
Germany) 
Microscope glass slides R. Langenbrinck, Emmendingen 
Nitrocellulose Transfer membrane Whatman (Dassel, Germany) 
One-way pipette (2-50ml) Greiner GmbH (Frickenhausen, 
Germany) 
Parafilm American National Can (WI, USA) 
Pasteur pipettes Poulten & Graf (Wertheim, Germany) 
PCR thin wall reaction tubes Eppendorf (Hamburg, Germany) 
Reaction tubes (1.5 and 2.0ml) Eppendorf (Hamburg, Germany) 
Pipette Tips (10-1000µl) Eppendorf (Hamburg, Germany) 
Pipette Filter Tips (10-1000µl) Eppendorf (Hamburg, Germany) 
Polypropylentubes (15 and 50ml) Greiner GmbH (Frickenhausen, 
Germany) 
Scalpel Feather Safety Razor (Osaka, Japan) 
Tissue Culture dishes (Ø10cm) Greiner GmbH (Frickenhausen, 
Germany) 
96-, 48-, 24-, 12-, and 6-well Plates Greiner GmbH (Frickenhausen, 
Germany) 
96-Well plates for UV measurement Greiner GmbH (Frickenhausen, 
Germany) 
96-Well plates for Fluorescence 
measurement 
Greiner GmbH (Frickenhausen, 
Germany) 
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3.1.3 Chemicals 
Acetic Acid Sigma-Aldrich (Munich, Germany) 
Acetone Merck (Darmstadt, Germany) 
Acrylamide/ bis-acrylamide, 30% solution Serva (Heidelberg, Germany) 
Agarose Serva (Heidelberg, Germany) 
Ammonium persulfate (APS) Sigma-Aldrich (Munich, Germany) 
Bacto-Agar Life Technologies (Darmstadt, Germany) 
Bromphenol blue, sodium salt Baaklab (Schwerin, Germany) 
Bovine serum albumin (BSA) Merck (Darmstadt, Germany) 
1M CaCl2 solution Sigma-Aldrich (Munich, Germany) 
ρ-coumaric acid Sigma-Aldrich (Munich, Germany) 
DAPI Roche (Mannheim, Germany) 
Deoxycholic acid Serva (Heidelberg, Germany) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (Munich, Germany) 
3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) 
Sigma-Aldrich (Munich, Germany) 
Draq5 Alexis Biochemicals  
EDTA, disodium salt Merck (Darmstadt, Germany) 
Ethanol 100% Merck (Darmstadt, Germany) 
Ethidium bromide (10mg/ml) AppliChem (Darmstadt, Germany) 
Fluorescein sodium salt Promega (Mannheim, Germany) 
G418 (Neomycin) Sigma-Aldrich (Munich, Germany) 
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Glycerol Sigma-Aldrich (Munich, Germany) 
Glycin Merck (Darmstadt, Germany) 
Hydrogen peroxide solution 30 % (w/w) 
in H2O 
Sigma-Aldrich (Munich, Germany) 
Isopropanol Merck (Darmstadt, Germany) 
Luminol (3-aminophtolhydrazide) Sigma-Aldrich (Munich, Germany) 
LY294002 Sigma-Aldrich (Munich, Germany) 
β-Mercaptoethanol AppliChem (Darmstadt, Germany) 
Methanol Merck (Darmstadt, Germany) 
1M MgCl2 solution Sigma-Aldrich (Munich, Germany) 
Mycophenolic acid (MPA) Gift of S.Urban, University of Heidelberg 
NaOH Merck (Darmstadt, Germany) 
Nonidet™ P40 substitute (NP-40) Roche (Mannheim, Germany) 
Paraformaldehyde (PFA) Sigma-Aldrich (Munich, Germany) 
PD98059 Sigma-Aldrich (Munich, Germany) 
Phalloidin Invitrogen (Karlsruhe, Germany) 
Phosphatase Inhibitor Cocktail 2 Sigma-Aldrich (Munich, Germany) 
Polybrene Sigma-Aldrich (Munich, Germany) 
Polyethylene glycol 8000 Sigma-Aldrich (Munich, Germany) 
Ponceau S Red Sigma-Aldrich (Munich, Germany) 
Protease inhibitor, complete, EDTA-free Roche (Mannheim, Germany) 
SB203580 Sigma-Aldrich (Munich, Germany) 
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SB431542 Sigma-Aldrich (Munich, Germany) 
Sodium dodecyl sulfate (SDS) Roth (Karlsruhe, Germany) 
SP600125 Sigma-Aldrich (Munich, Germany) 
N,N,N’,N’-tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich (Munich, Germany) 
Tris base Roth (Karlsruhe, Germany) 
Triton X-100 Sigma-Aldrich (Munich, Germany) 
Trypan blue Sigma-Aldrich (Munich, Germany) 
Tween-20 Bio-Rad Laboratories (Munich, Germany) 
U0126 Sigma-Aldrich (Munich, Germany) 
3.1.4 Solutions and Buffers 
4% PFA (w/v) (pH 7.4) Heat 500 ml PBS to 80 °C 
+ 4 % (w/v) Paraformaldehyde 
+ 0.2mM 1M CaCl2 stock solution 
+ 0.2mM 1M MgCl2 stock solution 
 
ECL solution 10ml 0,1 M TRIS buffer (pH = 8,5) 
50µl Luminol (250mM) 
22µl ρ-coumaric acid (90mM) 
3µl hydrogen peroxide solution 30 % (w/w) in H2O 
 
Cytomix 120mM KCl 
0.15mM CaCl2 
10mM potassium phosphate buffer (pH 7.6) 
25mM Hepes (pH 7.6) 
2mM EGTA 
5mM MgCl2, pH 7.6 (KOH) 
freshly added: 2mM ATP (pH 7.6) 
5mM glutathione 
 
Luciferase assay buffer 25mM glycyl-glycin (pH 7.8) 
15mM potassium phosphate buffer (pH 7.8) 
15mM MgSO4 
4mM EGTA 
freshly added: 1mM DTT and 2mM ATP 
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Luciferase lysis buffer 1 % (w/v) Triton X-100 
25mM glycyl-glycin (pH 7.8) 
15mM MgSO4 
4mM EGTA 
freshly added: 1mM DTT 
 
Renilla luciferase substrate 
solution 
luciferase assay buffer without DTT and ATP 
freshly added: coelenterazine solution 1:700 
 
MTT staining solution PBS 
+ 5mg/ml MTT 
 
MTT stop solution DMSO 
+ 10% SDS 
+ 0.6% acetic acid 
 
DNA loading buffer 35% Glycerol 
1x TAE buffer 
Spatula tip bromphenol blue 
 
50x TAE buffer 242g Tris base 
57.1ml Glacial Acetic Acid 
18.6g EDTA, sodium salt 
Add 1l distilled H2O 
 
RIPA buffer 1.815g Tris base 
4.383g NaCl 
6ml Nonidet P40 
0.279g EDTA, sodium salt 
0.3g SDS 
1.6g Deoxycholic acid, sodium salt 
Add 300ml distilled water, adjust to pH 7.2 
 
pre-working solution: 
50ml RIPA + 1tablet of Complete Protease Inhibitor 
→aliquot it to 5ml 
 
working solution: 
5ml RIPA (with Complete) + 50µl Phosphatase 
Inhibitor Cocktail 
 
10x TBS 12.1g Tris base 
87.66g NaCl 
Add 1l distilled water, adjust to pH 7.6 
 
TBST 1x TBS 
10ml 10% Tween-20 
Add 1l distilled water 
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10x Lämmli 144g Glycin (192 mM) 
30.34g Tris base (125mM) 
100ml 10% SDS 
Add 1l distilled water 
 
5x Protein loading buffer 2,5ml β-Mercaptoethanol (12,5%) 
2g SDS (10%) 
10mg Brom Phenol Blue 
6ml 1M Tris HCl pH6,8 (0,3M) 
200µl 500mM EDTA (5mM) or 1ml of 100mM EDTA 
10ml 99%Glycerin (50%) 
1,3ml H2O 
add 20ml distilled wáter 
 
10x Transfer buffer 144g Glycine (192 mM) 
60.72g Tris base (250 mM) 
Add 1l distilled water 
 
1x Transfer buffer 100ml 10x Transfer buffer 
200ml Methanol (20%) 
Add 1l distilled water 
 
 
Blocking buffer 1% BSA (w/v) in PBS 
 
Permeabilization buffer 0,3% (v/v) Triton-X 100 in PBS 
 
Stripping buffer 0.2M NaOH 
 
3.1.5 Reagent and Biological Kit 
Biorad Protein Assay kit Bio-Rad (munich, Germany) 
Competent E.coli One Shot TOP 10 Invitrogen (Karlsruhe, Germany) 
Dulbecco's Modified Eagle's Medium 
(DMEM) With high glucose, w/o L-
glutamine 
Lonza Group Ltd. (Cologne, Germany) 
DNA Ladder AppliChem (Darmstadt, Germany) 
FastStart Polymerase Roche (Mannheim, Germany) 
Fetal Calf Serum (FCS) Invitrogen (Darmstadt, Germany) 
Fluorescent Mounting Medium DakoCytomation (Hamburg, Germany) 
Hank’s Buffered Salt Solution (HBSS) PAA Laboratories (Cölbe, Germany) 
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Lipofectamine 2000 Invitrogen (Darmstadt, Germany) 
L-glutamine 200mM PAA Laboratories (Cölbe, Germany) 
Mini-/ Maxi-Plasmid Extraction Kit Qiagen (Hilden, Germany) 
Opti-MEM® I reduced serum medium Invitrogen (Karlsruhe, Germany) 
Penicillin/streptomycin 
10,000U/10,000µg/ml  
PAA Laboratories (Cölbe, Germany) 
Prestained Protein Ladder Fermentas (St.Leon-Rot, Germany) 
RNAiMax Invitrogen (Karlsruhe, Germany) 
Reporter Lysis buffer Promega (Mannheim, Germany) 
RNeasy Mini Kit Qiagen (Hilden, Germany) 
RNeasy QuantiTect Reverse 
Transcription Kit 
Qiagen (Hilden, Germany) 
TaqMan® Universal PCR Master Mix Applied Biosystems (CA, USA) 
10x Trypsin-EDTA PAA Laboratories (Cölbe, Germany) 
Venor®GeM Mycoplasma PCR Detection 
Kit 
Minerva Biolabs (Berlin, Germany) 
3.1.6 Media 
Huh7 Growth Medium DMEM 
+ 10% FCS 
+ 2mM Glutamine 
+ 100U/ml resp. 100g/ml 
Penicillin/Streptomycin 
 
HepG2/2.15 Growth Medium William E medium 
+ 10% heat-inactivated FCS 
+ 2mM Glutamine 
+ 100µM non-essential amino acids 
+ 100U/ml resp. 100g/ml 
Penicillin/Streptomycin 
 
PHH1 Medium William E medium 
+ 25mM hydrocortisone 
+ 2.5µg of insulin/ml 
+ 2mM glutamine 
+ 10% FCS 
+ 2% dimethyl sulfoxide 
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PHH2 Medium William E medium 
+ 25mM hydrocortisone 
+ 2.5µg of insulin/ml 
+ 2mM glutamine 
+ 0.5% dimethyl sulfoxide 
 
LB Medium 1% (w/v) NaCl 
1% (w/v) Yeast extract 
0.5% (w/v) Trypton 
 
LB agar 1.5% Bacto-agar in LB medium 
(autoclave and add antibiotics) 
 
3.1.7 Cells 
HepG2 
HepG2 cells were derived from a 15-year-old white male from Argentina with 
differentiated hepatocellular carcinoma by the group of Aden et al. in 1979. HepG2 cells 
are epithelial-like and grow as monolayers and in small aggregates [128]. HepG2 cells 
are completely resistant to TGF-β-induced apoptosis [129]. 
HepG2.2.15 
HepG2.2.15 cells were derived from HepG2 cells by Sells et al. in 1987. HepG2 cells 
were stably transfected with a plasmid carrying the gene that confers resistance to G418 
and four 5'-3' tandem copies of the HBV genome. HepG2.2.15 cells support the 
assembly and of the replicative intermediates of HBV DNA and of Dane-like particles 
[67]. It should be noted that the transfection of HepG2 cells to create HepG2.2.15 cells 
occurred when HepG2 cells were already transformed and thus may not directly reflect 
the development of HCC in hepatocytes that have been naturally infected with HBV 
[130]. All experiments with these cells were performed in the S2 laboratories of S.Urban 
(Department of Virology, University of Heidelberg) due to safety issues. 
Huh7 
Huh7 cells were derived from a 57-year-old Japanese male with a well differentiated 
hepatocellular carcinoma by the group of Nakabayashi et al. in 1982. Huh7 cells are 
epithelial-like and grow in monolayers [131]. Huh7 cells are sensitive to TGF-β-induced 
apoptosis [47] [132]. 
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Huh7.5 
Huh7.5 cells were derived from Huh7 cells by Blight et al. in 2002. Huh7 cells 
transfected with subgenomic HCV replicons were cured of HCV RNA by prolonged 
treatment with IFN-α. Cured Huh7 cells were electroporated with subgenomic RNA 
replicons and selected by G418, resulting in the Huh7.5 cell line, which is highly 
permissive for HCV replication [133].  All experiments with these cells were performed 
by Daniel Rupp in the S3 laboratories of R.Bartenschlager (Department of Virology, 
University of Heidelberg) due to safety issues. 
Primary human hepatocytes 
Primary human hepatocytes from liver resections were obtained from patients 
undergoing partial hepatectomy. Experimental procedures were performed according to 
Human Tissue and Cell Research Foundation guidelines. Informed patient consent was 
approved by the Ethical Committee of the University of Munich (Munich, Germany). 
PHHs were isolated, as previously described [134] and seeded at 1× 105 cells/cm2 in 12-
well plates. After arrival of PHHs, cells were put on PHH1 medium supplemented with 
10% FCS and 2% dimethyl sulfoxide (DMSO), prior to infection with HBV. Experiments 
with HBV-infected PHHs were performed in the S2 laboratories of S.Urban (Department 
of Virology, University of Heidelberg) due to safety issues. 
HEK293A 
Human embryonic kidney cells which are transformed by sheared human adenovirus 
type 5 DNA. These cells are used as packaging system for the expansion of adenovirus 
and were obtained from Invitrogen (Karlsruhe, Germany). 
 
3.1.8 Plasmids 
HCV core 
pBICEP-CMV-2 (bicistronic expression vector used for stable transfection from Sigma-
Aldrich, Munich, Germany) plasmid encoding HCV core protein isolated from tumor liver 
tissue of a patient with HCV-related HCC (kindly provided by S.Battaglia, Inserm, Unite´ 
785, Villejuif, France). 
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β-Gal plasmid 
β-galactosidase expression vector (pCR3lacZ) (Invitrogen, Karlsruhe, Germany). 
CAGA reporter plasmid 
pGL3 basic plasmid (Promega, Mannheim) encoding 9 repetitions of the CAGA 
sequence (Smad-binding-sites SBE from the PAI-I promoter) in the promoter region of a 
firefly luciferase [135].  
Smad7 promoter reporter plasmid (-1280) 
pGL3-Basic Vector encoding a firefly luciferase under control of the mouse Smad7 
promoter (region -1276 to +41) [136]. 
HCV viral construct pFK-RLuc-2A-core-Jc1 (JcR-2A) 
monocistronic full length reporter virus; RLuc is fused in-frame to the N-terminal 16 aa of 
the core protein with the foot-and-mouth disease virus (FMDV) 2A peptide to trigger 
proteolytic removal between the luciferase and the following complete Jc1 open reading 
frame 
3.1.9 Polyacrylamide gels 
Compounds for 2 mini gels 4% stacking gel 10% resolving gel 
30% Acrylamide 0.83ml 6.7ml 
Tris pH 8.8 - 5ml 
Tris pH 6.8 0.63ml - 
10% SDS 50µl 200µl 
H2O 3.4ml 7.9ml 
10% APS 50µl 200µl 
TEMED 5µl 8µl 
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3.1.10 Primer 
TaqMan® Real Time PCR 
TGF-β1 (Hs00171257_m1) Applied Biosystems (CA, USA) 
rS18 (Hs03003631_g1 Applied Biosystems (CA, USA) 
 
Conventional PCR 
Protein (product size bp) Sequence 5’  3’ 
p15 (299/422 bp) For: TTTCGGGAGGCGCGCGAT 
Rev: GCTGGGGAACCTGGCGTCAG 
 
GADD45β (290bp) For: AGGATCGCCTCACAGTGG 
Rev: CCGCACGATGTTGATGTC 
 
HCV core (264bp) For: TTACCTGTTGCCGCGCAGGG 
Rev: GACCTACGCCGGGGGTCAGT 
 
Bim (130bp) For: TAAGTTCTGAGTGTGACCGAGA 
Rev: GCTCTGTCTGTAGGGAGGTAGG 
 
c-myc (381bp) For: AGCAGCTCGAATTTCTTCCA 
Rev: GAAACTTTGCCCATAGCAGC 
 
β2MG (290bp) For: CTCACGTCATCCAGCAGAGA 
Rev: CAAACCTCCATGATGCTGC 
 
3.1.11 Antibodies 
Akt (#9272) Cell Signaling (Frankfurt, Germany) 
Bcl-2 (#2870) Cell Signaling (Frankfurt, Germany) 
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Bcl-xL (#2764) Cell Signaling (Frankfurt, Germany) 
Cleaved PARP (#9542) Cell Signaling (Frankfurt, Germany) 
CTGF (#14939) Santa Cruz (Heidelberg, Germany) 
E-Cadherin (#610181) BD Bioscience (Heidelberg, Germany) 
hepatitis B core antigen (HBcAg)-specific 
polyclonal antibody (H363) 
kind gift from S.Urban, Department of 
Virology, University of Heidelberg, 
Germany 
p21 (#P1484) Sigma-Aldrich (Munich, Germany) 
p38 (#9212) Cell Signaling (Frankfurt, Germany) 
Phospho-p38 (#4631S) Cell Signaling (Frankfurt, Germany) 
Phospho-Akt (#4060P) Cell Signaling (Frankfurt, Germany) 
Phospho-c-jun (#9261S) Cell Signaling (Frankfurt, Germany) 
pErk (#7383) Santa Cruz (Heidelberg, Germany) 
Phospho-Smad1/3 (#1880-1) Epitomics/ Biomol 
Phospho-Smad2 (#3101) Cell Signaling (Frankfurt, Germany) 
Smad3 (#51-1500) Invitrogen (Karlsruhe, Germany) 
Smad7 (#11392) Santa Cruz (Heidelberg, Germany) 
Tubulin (#4074-100) Abcam (Cambridge, UK) 
Vimentin (#20346) Abcam (Cambridge, UK) 
ZO-I (#40-2200) Invitrogen (Karlsruhe, Germany) 
goat anti-rabbit IgG-HRP Santa Cruz (Heidelberg, Germany) 
goat anti-mouse IgG-HRP Santa Cruz (Heidelberg, Germany) 
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donkey anti-goat IgG-HRP Santa Cruz (Heidelberg, Germany) 
AlexaFluor 488 (green), 555 (red), 
633 (far red) 2’ AB 
Invitrogen (Karlsruhe, Germany) 
 
3.1.12 Adeno-/ Lentivirus 
AdLacZ Adenovirus expressing bacterial β-galactosidase under the 
control of a CMV promoter (kindly provided by C.H.Heldin, 
Department of Medical Sciences, Clinical Chemistry, Uppsala, 
Sweden) 
AdSmad7 Adenovirus encoding human Smad7 cDNA fused with the Flag 
epitope sequence under the control of a CMV promoter (kindly 
provided by C.H.Heldin, Department of Medical Sciences, Clinical 
Chemistry, Uppsala, Sweden) 
AdSmad3 Adenovirus encoding human Smad3 cDNA fused with the Flag 
epitope sequence under the control of a CMV promoter (kindly 
provided by C.H.Heldin, Department of Medical Sciences, Clinical 
Chemistry, Uppsala, Sweden) 
Leshp38 Lentivirus expressing shRNA targeting sequences in the MAPK 
p38 (kindly provided by S.Urban, Department of Virology, 
University of Heidelberg, Germany) 
Leshcontr-1 Lentivirus expressing shRNA predesigned from Dharmacon, 
containing at least four mismatches to all known human genes 
(kindly provided by S.Urban, Department of Virology, University 
of Heidelberg, Germany) 
3.1.13 Cytokines 
Human recombinant TGF-β1 Peprotech (Hamburg, Germany) 
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3.1.14 siRNA 
Smad3 siRNA Qiagen (Hilden, Germany) 
Control siRNA Qiagen (Hilden, Germany) 
p38 MAPK shRNA 5`-GGAAUUCAAUGAUGUGUAUUU-3 
Control shRNA Dharmacon (Waltham, USA) 
 
3.2 Methods 
3.2.1 Cell Culture 
Maintenance of Cells 
For maintenance of cell lines, cells were grown at 37°C and 5% CO 2 in a humid 
atmosphere in T-flasks containing DMEM growth medium until cells reached a 
confluence of about 80%. In order to adjust the media prior usage, growth medium was 
adapted to 37°C. Medium was removed from the cells and cells were washed with room 
tempered HBSS, in order to remove left medium, which may negatively influence the 
effect of subsequent trypsinization. After washing, Trypsin/EDTA (1x) solution was 
added to the cells and the flask was put back into the incubator. The Trypsin/EDTA is 
needed to disrupt the Ca2+-dependent cell-cell-contacts and to obtain a single cell 
suspension. The enzymatic reaction was stopped when cells detached by adding 
medium containing 10% FCS. Corresponding to a seeding density of around 30%, part 
of the cell suspension was plated out in a T-flask and placed back into the incubator. 
Every 3-4 days, conditioned medium was replaced by fresh room tempered growth 
medium until cells reached 80% confluence. 
Determination of Cell Number 
For experiments which require a defined cell number, cells were counted by means of a 
Neubauer hemacytometer. Therefore, cells were trypsinized and cell suspension was 
collected in a Falcon tube. Then, 20µl of this suspension were mixed with 20µl of 0.05% 
trypan blue in PBS (ratio 1:2). 10µl of this suspension were filled into each side of the 
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Neubauer hemacytometer and the viable unstained cells were counted immediately 
under the microscope. Cells were counted by the following calculation: 
Viable cell count / number of squares * dilution factor * 104 = viable cells/ ml 
Cell Harvest and Lysis 
For cell harvest culture dishes were plated on ice. The medium was removed and the 
cells were washed with cold HBSS. An appropriate volume of RIPA cell lysis buffer was 
added onto the wells and the culture dish was frozen immediately at -80°C for 1h in 
order to break cell walls. Subsequently, cell suspension was scraped and collected in a 
1.5ml Eppendorf tube. Cell debris were pelleted by centrifugation for 10min at 
13,000rpm and 4°C in a biofuge. Supernatant was tra nsferred into a new Eppendorf 
tube and stored at -80°C until usage. 
Thawing of Cells 
The vial containing the cryopreserved cells was placed into a 37°C waterbath and 
rotated gently until the content was completely thawed. Immediately, cells were 
transferred into a T-flask with growth medium in a seeding density of 5500 cells/cm2 and 
placed into the incubator at 37°C and 5% CO 2. After 4h of cultivation, cells had attached 
to the Bottom of the T-flask. Conditioned medium was replaced by fresh growth medium 
to remove the residual DMSO and unattached cells. The medium was then changed 
every 3-4 days thereafter, until the culture was approximately 80% confluent and 
subculturing of the cells had to take place. 
Freezing of Cells 
Cells were frozen in a concentration of 1x106 cells/ml. Briefly cells were suspended in 
freezing medium and transferred into a cryotube, which was placed into the ultra-low 
freezer at -80°C in an isopropanol-freezer-box. The  next day, cryotubes were put into 
liquid nitrogen for infinite storage. 
Kill Curve 
For determination of the appropriate amount of antibiotic G418, which leads to cell 
death, the cells were plated on a 12-well plate (70% confluence) in 1ml medium one day 
prior to antibiotic treatment. The next day, cells were treated with different 
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concentrations of G418 (0 - 1000µg/ml). After 2 days, cells were regarded under the 
microscope and number of dead cells in comparison to viable cells was estimated 
roughly. Subsequently, fresh medium was applied to the cells with appropriate 
concentration of selective antibiotic and plates were incubated again for 2 days until 
second estimation of cell numbers could be performed. This was repeated, until lowest 
concentration of G418 was determined which results in death of all cells. 
Transduction of Cells 
For transduction, cells were plated in 12-well plates in a seeding density appropriate to 
the duration of the corresponding experiment in growth medium. Transduction took 
place the next day. Adenovirus was added in a concentration of 50ifu/cell and incubated 
for 2h. For transduction with Lentivirus, cells were incubated with virus particles in the 
presence of polybrene (8µg/ml) for 24h. After incubation, cells were washed with HBSS 
once and starvation medium was added. Proper overexpression/ downregulation of the 
protein was proven after 2-3 days cultivation. 
Transfection of Cells 
For transient transfection of Cell lines with 10nM/24-well siRNA or 1µg/24-well plasmid 
DNA, respectively, cells were plated with the appropriate cell number in growth medium 
w/o antibiotics one day before transfection. The transfection was carried out as follows: 
siRNA or plasmid DNA was mixed with Opti-MEM® I reduced-serum medium in a 
concentration according to the manufacturers’ protocol. Then RNAiMax or Lipofectamine 
2000, respectively, was added at an amount to obtain a suitable ratio of siRNA or 
plasmid DNA to transfection reagent (e.g. 2:6, 2:8), mixed and incubated for 20min at 
room temperature. The medium of the cells was exchanged for fresh medium containing 
no FCS and no antibiotics. The transfection mix was added dropwise to the cells and 
swayed gently to disperse the mixture. Six hours after transfection the medium was 
replaced again. In case of plasmid DNA transfection, Transfection efficiency was 
checked by cotransfection of ß-Gal plasmid via expression of ß-galactosidase under 
control of a CMV promoter. For investigation of proper transfection of siRNA, cells were 
harvested 72 hours after transfection and silencing of the respective gene product was 
detected by means of western blot analysis. 
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Selection of stably transfected cells 
At 48hrs after transfection of cells with the plasmid of interest containing a resistance 
gene against neomycin, cells were put on medium containing 400µg/ml neomycin. 
Medium was changed every 2-3 days and selection was performed for at least 21 days. 
HBV Infection of PHHs 
HBV infection of PHHs was done in 12-well plates. PHHs were kept in PHH1 medium. 
Inoculation was with 500µl of medium containing 4% PEG 8000 and 10µl of the 
concentrated HBV virus stock for 16 hours at 37°C. The next day, PHHs were washed 3 
times with PBS and further cultivated for 8 days with PHH-2 medium (Figure 3.1). 
Medium was refreshed every second day. 
 
 
 
Figure 3.1: Experimental setup of HBV infection of PHHs with subsequent TGF-β treatment (5ng/ml). 
Immediately upon receipt of PHHs, cells were infected with HBV for 16hrs. The next day, cells were 
washed with PBS and cultivated for 8 days. Medium was refreshed every second day and samples of the 
supernatant for HBsAg and HBeAg measurements were taken. TGF-β treatment for 24hrs was performed 
on day 7, treatment for 1h on day 8 until all samples were harvested. The experiments were performed 
three times independently, each experiment with PHHs of another donor. RNA was isolated and subjected 
to microarray analysis at the core facility of the Medical Faculty Mannheim, University Heidelberg. 
 
Electroporation of Huh7.5 cells with HCV RNA 
Cells were washed once with PBS, trypsinized and sheared by pipetting up and down 
through a 1,000µl tip to get single-cell suspensions. After washing once with DMEM 
complete (5min at 700 rpm) and once with 50ml PBS (5min at 700 rpm) Huh7.5 cells 
were resuspended at 1.5 x 107 cells per ml in Cytomix. 10µg of in vitro transcribed RNA 
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were mixed with 400µl cell suspension and electroporated in a cuvette with a gap width 
of 0.4cm (Bio-Rad) at 975µF and 270V. Cells were immediately transferred to 19ml 
DMEM complete and plated with 2ml per 6-Well. After 16h electroporation complete 
DMEM was exchanged by serum-free DMEM. The next day, cells were treated with 
5ng/ml TGF-β for 0, 1, and 24h. Then cells were harvested for Luciferase Assay to 
determine viral replication and for Western Blot analysis and RNA extraction, 
respectively. 
Immunofluorescence 
The expression of several cell markers was proven by immunofluorescence staining. 
Therefore, cells were grown on cover slips in 12-well plates. Medium was aspirated and 
washed with PBS. Fixation of cells was performed with 4% PFA for 20min at room 
temperature with subsequent treatment by 0.3% Triton X-100 for 5min. Afterwards, cells 
were blocked using 1% BSA in PBS for 1h to inhibit unspecific binding of the primary 
antibody. Incubation with first antibody diluted in 0.2% BSA in PBS was performed in the 
dark overnight at 4°C. The next day, cover slips we re washed 3 times with PBS and 
subsequently incubated with a mixture of secondary antibody (1:300 in 0.2% BSA in 
PBS) and Draq5 (1:5000) for 1h in the dark at room temperature. Afterwards, cover slips 
were washed with PBS (3 times) and placed up-side-down into mounting medium on an 
object slide. Slides were dried and stored in the dark at 4°C until microscopy. 
Immunofluorescence analyses of HBcAg expression in infected cells. 
At 8 days post-infection, HBV-infected PHHs were washed with PBS, fixed with 4% 
paraformaldehyde for 20min, and treated with permeabilization buffer for 
30min.Afterwards, cells were washed and HBcAg-specific polyclonal antibody H363 was 
added (1:1,000 dilution in PBS containing 5% skim milk powder). After 2h of incubation 
at 4°C, the cells were washed 3-times and incubated  in the dark for 1h at room 
temperature with 1:500-diluted Alexa Fluor 488-conjugated secondary mouse anti-rabbit 
antibody in PBS containing 5% skim milk powder. Cells were washed 3-times with PBS, 
incubated for 30min with 1µg DAPI and finally washed again 3-times with PBS. Images 
were acquired by means of confocal microscopy. 
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Phalloidin staining 
The formation of stress fibers was studied by Phalloidin staining. Therefore, cells were 
grown on cover slips in 12-well plates. Medium was aspirated and washed with PBS. 
Fixation of cells was performed with 4% PFA for 20min at room temperature with 
subsequent treatment by 0.3% Triton X-100 for 5min. Phalloidin was diluted 1:400 
concomitant with Draq5 (1:5000) in blocking buffer. The mixture was added onto the 
cover slips and incubated for 1h at room temperature in the dark. Afterwards, cover slips 
were washed with PBS 5min (3 times) and placed up-side-down into mounting medium 
on an object slide. Slides were dried and stored in the dark at 4°C until microscopy. 
Renilla-Luciferase assay 
Quantification of luciferase reporter activity (Renilla-Luciferase) was used to determine 
transient HCV RNA replication of the full-length virus construct JCR2a. Infected cells 
were harvested at the appropriate time points (see individual experiment description) by 
washing once with PBS and addition of ice-cold luciferase lysis buffer (350µl per 6-well, 
200µl per 12-well and 100µl per 24-well). Cells were frozen immediately and after 
thawing lysates were resuspended by pipetting. 
For measurement of cells out of 6-wells 100µl lysate were mixed with 360µl Renilla-
Luciferase substrate solution and measured for 10 sec in a luminometer. 
Promoter Reporter Assay 
For promoter reporter assays, cells were seeded in 24-well plates with an appropriate 
cell concentration. Cells were transfected (as described above) with plasmid containing 
the promoter of interest followed by the luciferase gene. 24h post-transfection, cells 
were treated with the substance of interest and incubated for another 24h. Then, cells 
were washed with PBS and 50µl of 2x Reporter Lysis Buffer was added to the wells. The 
plate was frozen at -80°C in order to disrupt cells . Afterwards, 20µl of cell lysate was 
transferred into a white 96-well plate and 50µl of Luciferase Assay Reagent was added. 
Luminescence was measured immediately in a microplate reader. 
β-Gal assay 
For measurement of β-Gal expression as e.g. an indicator for transfection efficiencies, 
cells were seeded in 24-well plates with an appropriate cell concentration. Cells were 
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transfected (as described above) with plasmid containing the LacZ gene. β-Gal Assay 
was performed using the β-Galactosidase Assay Kit from Promega according to the 
manufacturers protocol with slight modifications. Briefly, 48-72h post-transfection, wells 
were washed with PBS and 50µl of 2x Reporter Lysis Buffer was added to the wells. The 
plate was frozen at -80°C in order to disrupt cells . Afterwards, 20µl of cell lysate was 
transferred into a transparent 96-well plate and 20µl of Assay 2x Buffer was added. The 
plate was covered and incubated for 30min at 37°C u ntil a yellow color had developed. 
The reaction was stopped by adding 60µl of 1M Sodium Carbonate and absorbance was 
measured at 420nm in a microplate reader. 
MTT Assay 
For proliferation studies of cells, cells were seeded in 24-well plates with a seeding 
density of 5,000 cells/ well. After cell attachment, medium was changed to starvation 
medium w/o FCS and incubated overnight (37°C, 5% CO 2). The next day, cells were 
treated with TGF-β for 48h. Then, 5mg/ml MTT solution was added to each well (final 
concentration 500µg/ml) and incubated for 4h, to allow metabolization of yellow MTT to 
purple formazan. MTT is a pale yellow colored substance, which is converted into a blue 
formazan crystal by a dehydrogenase enzyme located in the mitochondrion of viable 
cells. The blue formazan crystals accumulate within the cells and its amount can be 
quantified. Therefore, supernatant of each well was removed carefully without disrupting 
cells and MTT solvent was added to resolve formazan crystals. The plate was shaken in 
the dark for 2h at room temperature till measurement of absorbance at a wavelength of 
560nm against a reference wavelength of over 650nm. MTT solvent was used as 
negative control.  
LDH Assay 
Upon cell death, triggered by necrosis or apoptosis, cell membrane becomes permeable 
which leads to release of lactate dehydrogenase into the supernatant. This enzyme 
converts lactate into pyruvate thereby converting NAD+ into NADH+H+. The LDH assay 
utilizes the NADH+H+ for conversion of tetrazolium into formazan. Formazan is 
measured photometrically allowing conclusion on LDH activity and in turn on cell death 
rate. 
Cells were seeded in 96-well plates (100µl) and starved overnight until treatment with 
TGF-β (5ng/ml) for at least 24h. At the end of the experiment, 50µl of the supernatant 
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was transferred into a transparent 96-well plate and mixed with 50µl reagent from the 
Cytotoxicity Detection Kit from Roche. The plate was incubated in the dark and 
measured with a Tecan reader at 490nm. For determination of relative cell death rate, 
LDH release in the supernatant was measured only. For determination of absolute cell 
death rate, remaining viable cells of the control well were lysed in 100µl Triton X-100 
(1%). Fifty µl of this cell lysate were transferred and measured as well. 
LDH (supernatant) / (LDH (supernatant) + LDH (lysed cells)) * 100 = absolute cell death 
(%) 
The reagent of the Cytotoxicity Detection Kit was mixed immediately prior to usage, 
composed of catalyst and dye solution in a ration 1:45. 1% Triton X-100 and medium 
served as negative control. 
Migration Assay 
Effects of TGF-β on cell migration were determined by means of Transwell assays. 
Therefore, cells were grown on Ø10cm dishes one day prior in medium containing 1% 
BSA. The next day, cells were trypsinized and centrifuged (5min, 500g) and 
resuspended in 1 or 2ml medium (1% BSA) and counted. The frame wells of the 
Transwell Assay plate were filled with PBS (1.5ml) to prevent dehydration effects. For 
the lower wells (750µl/well) medium (1%BSA) was prepared containing either PBS 
(control) or 5ng/ml TGF-β. Then, transwells were placed into the wells. For the upper 
wells, 25,000 cells/well in medium (1% BSA) were suspended and PBS or TGF-β was 
added. The plate was incubated for 24h. The next day, cells of the upper and the lower 
wells were collected carefully by trypsinization in 200µl and transferred into a white 96-
well plate. The plate was centrifuged (10min, 10,000rpm) and supernatant was 
discarded. ATP solution (40µl) was added to the cells and luminescence was measured. 
3.2.2 Microbiological Methods 
Transformation of bacteria 
In order to amplify plasmid DNA, competent bacteria were transformed with the plasmid 
of interest. Therefore, 1µg purified plasmid DNA was added to the transformation mix. 
The procedure was then performed as described in the manual provided by the 
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manufacturer (Invitrogen). Briefly, after incubation of the transformation mix for 30min on 
ice, heat-shock was performed for 40sec at 42°C. Af ter another 3min on ice the 
transformation mix was incubated with S.O.C medium for 1h at 37°C in a shaker at 
220rpm. Then 50µl of bacterial suspension was plated on agar plates consisting of 1% 
bacto-agar, LB-Medium and the appropriate antibiotic. The added antibiotic allowed only 
such bacteria to grow, which had taken up the plasmid of interest containing the 
resistence gene. The plates were then incubated at 37°C for at least 16h, but not longer 
than 20h, in order to obtain single colonies. Individual colonies were then picked for 
subsequent bacterial culture. 
Bacterial culture of transformed bacteria 
To obtain the plasmid DNA in an adequate amount, a single colony was picked from a 
plate to inoculate LB-Medium containing the appropriate selective antibiotic. For 
subsequent miniprep, 5ml of LB-Medium was inoculated. For maxiprep 200ml LB-
medium were inoculated with 100µl of the 5ml culture used for miniprep. The culture 
was then incubated in a bacteria shaker for 20h at 37°C and 220rpm. 
Plasmid DNA extraction (mini-/maxiprep) from bacteria 
For miniprep 1ml bacteria culture was transferred into a 1.5ml-Eppendorf tube and 
centrifuged for 5min at 4000 rpm in a biofuge. The supernatant was discarded and 
plasmid DNA was extracted from the bacteria pellet as described in the Qiagen miniprep 
manual. This method is based on adsorption of the DNA to a matrix. For maxiprep 
200ml of bacterial culture were centrifuged for 5min at 6000rpm and then DNA 
extraction was performed as described in the manual. 
The concentration of purified DNA was determined by optical density (OD) 
measurement. For this, the samples were diluted 1:20 in Millipore water and measured 
at wavelengths of 260nm and 280nm by means of a UV spectrophotometer against H2O 
as a blank. Thereby, 50ng/µl of double stranded DNA correspond to one unit of 
absorbance at 260nm (OD260=1). By the means of the formula 
DNA (µg/ml) = OD260nm × dilution factor × 50 
The DNA concentration was calculated using the software of the spectrophotometer. 
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3.2.3 Biochemical Methods 
Determination of Protein Concentration 
The determination of the protein concentration was performed in a 96-well plate by using 
the DC Protein Assay Kit® from Bio-Rad which is based on the Lowry method. For each 
sample triplicates were performed. The assay was carried out as follows: 20µl reagent 
A’ (freshly made from 1ml reagent A and 20µl reagent S) and 200µl reagent b were 
added to 2µl of the sample and incubated for 15min at room temperature. A standard 
curve made out of bovine serum albumin (BSA) solutions in the same buffer with known 
concentrations (0, 1, 2, 4, 8, and 10mg/ml) served as reference. The OD at 690nm was 
measured using Tecan multiplate reader and protein concentrations in the samples were 
calculated by the according software. 
3.2.4 Immunoblot Analysis 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
The samples with cell lysates were mixed with Lämmli loading buffer (5x). Denaturation 
of proteins with this buffer leads to a negative charge of proteins, which allows 
separation by electrophoresis. A defined amount of protein (e.g. 30µg) in 20µl lysis 
buffer was mixed with 5µl 5x Lämmli loading buffer and heated for 5min at 95°C. The 
samples were then ready for loading on a gel, or were stored at -20°C in the freezer until 
used. Then the polyacrylamide gel consisting of the resolving gel and the stacking gel 
was prepared (Sambrook and Russel). First, the compounds needed for the resolving 
gel were mixed. APS and TEMED were added last shortly before casting the gel into the 
chamber, because the two components initiate polymerisation within a few minutes. 
Immediately after casting the resolving gel, it was covered with isopropanol in order get 
rid of bubbles and to produce a smooth layer. After 15min the polymerization was 
completed and the isopropanol was washed off well with MilliQ water. Water remaining 
on the gel was removed with Whatman-paper without touching or disrupting the gel. 
Afterwards, the compounds for the stacking gel were mixed and APS and TEMED were 
added finally. A comb generating either 15 or 10 pockets was introduced into the 
stacking gel and the gel was allowed to polymerize for at least 30min. After 
polymerization the comb was taken out of the chamber and the pockets formed were 
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rinsed with MilliQ water in order to remove remaining acrylamide. The chamber was then 
placed into the electrophoresis system and filled with electrophoresis running buffer. The 
initial current was 50V in order to concentrate the probes at the border of the resolving 
gel. Once they entered the resolving gel, voltage was increased to 110V. The run of the 
gel was finished when the pre-stained protein marker was well separated and the 
loading dye reached the bottom of the gel. 
Blotting 
Immediately after terminating gel electrophoresis, the transfer of the separated proteins 
onto a protein-binding membrane made out of nitrocellulose occurred. Proteins transfer 
from the negative pole to the positive pole according to the charge of the proteins. 
Therefore, the gel was placed on 3 sheets of Whatman-paper in the sandwich cassette 
and the membrane was placed on top of the gel and covered with at least 3 sheets of 
Whatman-paper. It was important not to trap air bubbles between the membrane and the 
gel, as this would result in a diminished protein transfer. The stack of gel, membrane 
and Whatman-paper was placed into the blotting chamber filled with transfer buffer and 
run at 180mA for 3h. After blotting the membrane was washed 3× for 5min with TBST 
and was ready for further treatments. 
Incubation with antibodies 
The membrane was incubated for 30min in 5% milk in order to block unspecific binding 
sites of the antibodies. Afterwards, the membrane was washed 3× for 5min with TBST 
and was then incubated with the primary antibody o/n at 4°C. The next day the 
membrane was washed 3× for 5min with TBST and incubated for 1h at room 
temperature with a secondary antibody. Thereafter the membrane was washed 3× for 
15min with TBST and the immunoreactive bands were detected by means of the ECL 
solution and an Immunoblot Imaging System. 
Stripping of membranes 
If another protein had to be detected on the same membrane, it was necessary to 
remove the bound antibodies and ECL solution. Therefore, the membrane was washed 
with ddH2O and stripped with 0.2M NaOH for 5min. Subsequently, the membrane was 
washed again withddH2O, followed by TBST. Then the membrane was ready for 
incubation with another antibody. 
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3.2.5 Molecular Biological Methods 
Production, purification, and quantification of HBV particles 
HBV particles were provided by the lab of Prof Urban, Molecular Virology, University of 
Heidelberg. Production of HBV virus was performed as described previously [137]. 
Briefly, Medium of HepG2.2.15 or HepAD38 cells was collected between days 3 and 8. 
Precipitation of viral particles from cell culture supernatants was performed overnight at 
4°C with 6% polyethylene glycol 8000 (PEG 8000; Sig ma) and concentrated by 
centrifugation (12,000 × g, 60 min, 4°C). After suspension in 1/100 of the vo lume of 
PBS-10% fetal calf serum (FCS), the particle composition and the viron concentration 
were quantified by analytical cesium chloride density gradient centrifugation and DNA 
dot blot analysis [138]. Aliquots were stored at -80°C. 
Adenovirus preparation and quantification 
For amplification of human recombinant E1-deleted adenoviral vectors, HEK293A cells 
were grown in T175-flasks until 80% confluence. Cells were infected with 3x10*6 ifu and 
further cultivated for 3-4 days until cells had started to detach and die. This cytopathic 
effect is due to the production of adenovirus. To harvest the adenovirus, medium was 
aspirated and 5ml PBS was put on the cells. The falsk was frozen and thawed 3-times to 
break cells and release adenovirus. Finally, the supernatant was centrifuged to get rid of 
cell debris and 1ml aliquots were frozen at -80°C u ntil usage. 
Lentivirus preparation and quantification 
Lentivirus preparation was previously reported (Hepatology, 2012, 56, 9-16). In brief, 
shRNA, targeting p38 MAPK was subcloned into LeGO-G lentiviral vectors. Cell-free 
viral supernatants were generated by transient transfection of HEK293T packaging cells 
using the third generation packaging plasmids pMDLg, pRSV-Rev, and the envelope 
plasmid pVSV-G. 
 
In vitro transcription 
For production of in vitro transcripts of the individual constructs first 10µg of the 
respective plasmid DNA had to be linearized to prepare “run off” transcripts of the 
correct length. Constructs carrying the genomic ribozyme of hepatitis δ (δg) downstream 
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of the 5‟-end of the RNA were additionally digested with MluI, which cuts directly after 
the ribozyme sequence, in a reaction volume of 100µl. For purification, plasmid DNA 
was mixed with 20µl 3M sodium acetate (pH 6.0) in a total volume of 200µl and 
extracted twice with 200µl TE saturated phenol and once with 200µl chloroform. At each 
step, the sample was first mixed with a vortex and then centrifuged (5min, 13,000rpm) 
for proper separation of the organic and aqueous phases and the upper aqueous phase 
was transferred to a new Eppendorf tube. To precipitate the DNA, 2.5vol 100% ethanol 
were added and the sample was left at -20°C for at least 30 min. After centrifugation for 
20min at 13,000rpm at 4°C, the pellet was washed on ce with 200µl 70% ethanol (3min, 
13,000rpm), air-dried briefly and dissolved in 60µl RNase-free H2O.  
For in vitro transcription, 20µl 5 x RRL transcription buffer, 12.5µl 25mM rNTPs, 2.5µl 
RNasin (40U/µl) and 4µl T7 RNA polymerase (19U/µl) were added to the purified DNA. 
After incubation for 2 h at 37°C, again 2 µl of T7 RNA polymerase were added, followed 
by 2h incubation at 37°C. Transcription was termina ted by addition of 6µl of RNase-free 
DNase (1U/ml)) for 30min at 37°C. For purification of the RNA, 60µl 2M sodium acetate 
(pH4.5), 440µl H2O and 400µl water-saturated phenol were added. The sample was 
mixed with a vortex, left on ice for 10min and centrifuged at 4°C for 10min at 13,000rpm. 
The supernatant was transferred to a new Eppendorf tube and extracted again with 1vol 
chloroform (vortex, 5min at 13,000rpm). RNA was subsequently precipitated with 0.7vol 
isopropanol (15min at 13,000rpm), washed once with 70% ethanol (3min at 13,000rpm) 
and dissolved in 50µl RNase-free H2O. Agarose gel electrophoresis was used to check 
RNA integrity and the concentration was determined by measurement of the optical 
density at 260nm. 
 
Mycoplasma Assay 
The Venor GeM Mycoplasma Detection Kit was used for the detection of a mycoplasma 
contamination. Therefore, cells were grown until they had reached 100% confluence. 
Conditioned growth medium (500µl) was centrifuged for 5min at 1200rpm and 
supernatant (100µl) was heated for 5min at 95°C pri or to a second centrifugation of 5sec 
at 13000rpm. For the following PCR, 2µl of the supernatant was used. 
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Mastermix: 
Reagent Amount (1×) 
(µl) 
PCR grade H2O 15.3 
10× Reaction Buffer 2.5 
Primer/Nucleotide Mix 2.5 
Internal Control DNA 2.5 
Polymerase (5U/µl) 0.2 
Probe 2 
Total volume 23 
 
Photometrical Determination of Nucleic Acid Concentration 
The concentration of purified DNA was determined by optical density (OD) 
measurement. For this, the samples were measured at wavelengths of 260nm and 
280nm by means of a Tecan microplate reader against H2O as a blank. Thereby, 
50ng/µl of double stranded DNA correspond to one unit of absorbance at 260nm 
(OD260=1). By the means of the formula 
DNA (µg/ml) = OD260nm × dilution factor × 50 
The DNA concentration was calculated using Microsoft Excel. 
RNA Extraction 
In order to extract total RNA, medium was removed and the cells were rinsed with PBS. 
Cell lysis with subsequent RNA extraction was performed according to the RNeasy Mini 
Kit protocol from Qiagen. The concentration of RNA was measured as described above. 
RNA was considered to be of high purity if the ratio of the OD260/280 was higher than 2. 
The samples were then stored at -80°C. 
Cycles Temperature (°C) Time (sec) 
1x 94 120 
39x 
94 30 
55 30 
72 30 
 4 for ever 
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Synthesis of first strand DNA by reverse transcription 
For the first strand DNA synthesis up to 1µg of each RNA sample was transcribed using 
the QuantiTect® Reverse Transcription Kit from Qiagen. In order to remove genomic 
DNA, 1µg RNA in 12µl H2O was incubated with 2µl “genomic DNA wipeout” for 2min at 
42°C. Then, the reaction mixture, set up as describ ed in the following table, was added 
and incubated for 1h at 42°C. 
 
Reagent (conc.)  Amount (µl) 
5x RT-Puffer [µl] 4 
dNTP-Mix 5 mM each (0,5mM) [µl] 1 
Polymerase [µl] 1 
Template RNA 1µg in H2O + 
genomic DNA wipeout  
14 
total ad 20µl H2O [µl] 20 
Polymerase chain reaction (PCR) 
For amplification of cDNA, primers specific for the gene of interest were designed by 
means of the program Primer-BLAST from NCBI and ordered from Eurofins MWG 
Operon. Primers were diluted 1:10 and a mastermix was set up (see following table): 
 
 
Reagent (conc.)  Amount (µl) 
10x PCR Buffer [µl] 2 
dNTP-Mix 10 mM each (200 µM) [µl] 0.4 
Primer forward + reverse (0,2 µM) 1 
H2O ad 20µl 14.5 
FastStart (2,5 U / rct) 0.1 
cDNA (max 20ng) 2 
 
 
 
 
 
3 MATERIALS AND METHODS 
 
51 
The PCR conditions were as follows: 
 
Step Temperature (°C) Time (min) 
1 95 3:00 
2 94 0:45 
3 51 - 74 1:00 
4 72 1:00 
5 go to step 2→ × (27-36)   
6 72 5:00 
7 4 forever 
 
Transcripts of a housekeeping gene, like of ß2MG, were quantified as an endogenous 
control. For the linear range of ß2MG amplification cycle number 28 was determined to 
be most suitable.  
PCR products were loaded on a 1.5% agarose gel and evaluated under UV light. The 
results were quantified by densiometry using Image J (National Institutes of Health). 
 
Quantitative real-time polymerase chain reaction 
Expression levels of TGF-β were determined by means of Taqman Real Time PCR. 
Therefore, 2ng cDNA was used, however, for rS18 (housekepping gene) only 10pg were 
used. The final reaction volume was 20µl containing 10x TaqMan® Universal PCR 
Master Mix, 1µl gene specific Taqman probes, the appropriate amount of cDNA, filled up 
with ddH2O. The PCR conditions were as followed: 10min, 95°C   40cycles 15s, 95°C 
 1min, 60°C. 
The obtained results were evaluated by the corresponding software in order to subtract 
the background fluorescence signal and to obtain a baseline. The PCR cycle number at 
which fluorescence reaches a threshold value of 10 times the standard deviation of 
baseline emission is used for quantitative measurement. This cycle number is called the 
cycle threshold C(t)  and its value is inversely proportional to the initial amount of target 
cDNA. Since both the amount of total RNA added to each reverse transcription reaction 
tube (based on wavelength absorbance) and its quality (i.e., degradation) are no reliable 
parameters to estimate the amount of the respective mRNA in the RNA preparation 
used for RT-PCR, transcripts of a housekeeping gene are quantified as an endogenous 
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control. A housekeeping gene is involved in basic functions needed for the maintenance 
of the cell. Housekeeping genes are constitutively expressed (they are always turned 
ON), and it is postulated that the expression is similar in all cells. The amplification 
efficiencies of target and reference genes have to be determined in advance, to ensure 
that primer binding sites differ only to a low extent. Quantification is then performed 
using the ddC(t) method. For each experimental sample, the C(t) value of the 
housekeeping gene is subtracted from the C(t) value of the gene of interest resulting in 
the dC(t) value. The dC(t) value of the sample of treated cells is then subtracted from 
the dC(t) value of the sample referring as control, e.g., untreated cells, resulting in the 
ddC(t) value. This ddC(t) value is then transformed by the equation Exp=2-ddC(t), 
leading to the decrease or increase of mRNA levels respective to the sample. 
Agarose gel electrophoresis 
For evaluation of amplified cDNAs, agarose gel electrophoresis was performed using a 
1.5% agarose gel. For this, agarose was dissolved in TAE buffer by heating in the 
microwave. After dissolving the solution was cooled to ~60°C, Ethidiumbromide 
(10,000X) was added and the gel was cast in a tray with a comb. After gelling, the gel 
chamber was filled with TAE buffer and 20µl of PCR amplification mix was pipetted into 
the pockets. The gel chamber was then connected to a power supply and run at 100V 
for the appropriate time. Finally, the gel was photographed under UV light. 
Measurement of HBsAg and HBeAg secretion 
For quantification of expressed and secreted HBsAg and HBeAg, supernatants of 
infected PHHs were collected between days 3 and 7 and measured quantitatively 
(ARCHITECT, IU/mL; Abbott) at the core facility of the Universitätsklinikum Heidelberg, 
Analytical Laboratories. HBsAg levels were measured in IU/ml and HBeAg in relative 
light units (RLU). 
3.2.6 Microarray analysis 
Microarray Hybridization 
RNA extraction was performed as described above using the RNeasy kit from Qiagen.  
The 28S/18S ratios of total RNA samples were assessed with the Bioanalyzer 2100 
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(Agilent) to ensure that quality was comparable between samples. Of each sample, 
150ng of total RNA were used to prepare cDNA according to the Ambion WT 
Expression Kit. Following cDNA-Cleanup, 5.5µg ssDNA were fragmented, labeled (WT 
Terminal Labeling and Controls Kit, Affymetrix) and hybridized for 17h at 45°C. 
GeneChip Human Gene 1.0 ST Arrays (Affymetrix) were washed and stained in the 
Affymetrix Fluidics Station 450. Fluorescence intensities of the hybridized arrays were 
acquired with the GeneChip Scanner 3000 and the operating software AGCC 
(Affymetrix). 
Microarray Data Analysis 
Microarray raw data were pre-analyzed and normalized, respectively, by the core facility 
of the Universitätsklinikum Mannheim. Genomic data were analysed by encapsulated R 
application [139]. In brief, from the pre-analyzed data, probesets with low variability were 
filtered out by means of median absolute deviation (MAD). Remaining probesets were 
further processed, only if the p-value of a statistical test (Student’s t-test, Wilcoxon 
signed-rank test) was be below a certain threshold (p < 0.05) and second, the fold-
change of groups compared were greater than a value specified (>1.3-fold or <−1.3-
fold). The list of significant altered genes were assigned to their corresponding pathways 
by means of KEGG or GO. Subsequently, significantly affected pathways were identified 
by applying a statistical test to a contingency table. 
3.2.6 Confocal Microscopy 
Confocal imaging was performed with a Leica laser scanning spectral confocal 
microscopy (model DM IRE2) equipped with an oil objective (HCX PL Apo 40x/1.32), an 
argon laser (488nm), a krypton laser (568nm), and a helium/neon laser (633nm). 
Images were developed with a TCS SP2 scanner and Leica Confocal software (Version 
2.5). 
3.2.7 Statistical Analysis 
All experiments were performed independently and at least three times. Obtained results 
are represented in means ± SE. Significant difference of results was determined by 
means of Student’s t-test and indicated with *p<0.05 and **p<0.02. 
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4 RESULTS 
4.1 Impact of HBV infection on TGF-β signaling in human 
hepatocytes 
HCC is a heterogeneous disease regarding etiology as well as biologic and clinical 
behavior. Chronical HBV infection leads to fibrosis and often ends in HCC [140, 141]. 
TGF-β is a profibrotic cytokine playing a pivotal role in cell signaling in liver upon liver 
damage. However, a direct role of HBV mediated changes on TGF-β signaling outcome 
towards oncogenicity has yet to be determined. To address this question, two 
approaches were made. To study the effects of HBV infection and TGF-β on the 
transcriptome, PHHs were infected with HBV and treated with TGF-β. Isolated RNA was 
subjected to microarray chips and results were evaluated by encapsulated R application. 
HepG2.2.15 cells are stably transfected with the HBV genome and produce HBV 
particles, thereby mimicking effects induced by HBV proteins after HBV infection. For 
verification of microarray results, HepG2.2.15 cells were investigated regarding the 
functional impact of HBV on TGF-β signaling pathway.  
 
4.1.1 HBV infection impairs TGF-β signaling in primary human 
hepatocytes 
Most of the reported studies investigating the mechanisms of HBV induced HCC have 
concentrated on cell culture systems expressing HBV or if PHHs were used, infection 
efficiency with HBV was only up to 50%. However, the infection protocol established in 
the group of Prof Urban, results in infection efficiency of nearly 100% [142], and 
presents an advantage in comparison to other investigational models established 
before. 
cDNA microarrays are powerful tools to identify disease related gene expression profiles 
in biological samples, as well as interactions between pathogenic organisms and their 
host cells.  
To provide new insight into the molecular mechanisms of HBV and to improve our 
understanding of TGF-β signaling in the pathogenesis of HBV infection, I performed a 
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cDNA microarray of PHHs infected with HBV or not upon TGF-β treatment (5ng/ml) and 
compared the alterations in the gene expression profiles comprehensively. 
 
4.1.1.1 HBV infection and TGF-β treatment of PHHs 
PHHs were infected with HBV as described in 3.2.1. The efficiency of HBV infection of 
PHHs was shown by immunofluorescence staining of HBV core antigen (green) on day 
8 post-infection. Nearly 100% of PHHs were infected with HBV (Figure 4.1) 
 
  
Figure 4.1: IF staining of HBV core antigen (green). Nuclear staining was done by DAPI (blue). (A) HBV 
infected hepatocytes on day 8 post-infection (magnification 400x). (B) Uninfected PHHs (magnification 
100x). One shown as representative. 
 
To verify HBV replication, the supernatant of HBV infected PHHs was collected every 
second day and HBsAg and HBeAg levels were measured. HBsAg and HBeAg levels 
increased steadily during the cultivation time, indicating that PHHs were infected with 
HBV and supported its replication. HBsAg levels were only slightly different in the three 
donors (Figure 4.2 A); ranging from 30IU/ml on day 3 up to 420IU/ml on day 7 post-
infection. HBeAg values (Figure 4.2 B) ranged from 50 on day 3 up to 6600 (donor #1), 
3000 (donor #2), 500 (donor #3) on day 7. HBeAg values differed within the donors, 
which might be due to individual patient dependent differences influencing HBV infection 
and replication. 
 
 
A B 
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Figure 4.2: HBsAg and HBeAg levels of HBV infected PHHs. To observe HBV replication, HBV 
antigens were measured quantitatively in duplicates in the supernatant of HBV infected PHHs every 
second day. (A) HBsAg and (B) HBeAg levels of the three donors #1, #2, #3.  
 
4.1.1.2 Microarray analysis and statistics 
To ensure that experiments are performed on PHHs of the same age, HBV infected 
PHHs were treated with TGF-β for 0 and 1h on day 8 post-infection and for 24 h already 
on day 7 post-infection, respectively. On day 8 post-infection, cells were then harvested, 
mRNA was isolated and microarray hybridization was performed according to the 
manufacturers’ protocol. After pre-analyzation and normalization of microarray raw data 
by the in-house core facility ZMF, genomic data were evaluated by encapsulated R 
application [139], including unspecific filtering, followed by statistical tests and pathway 
analysis (Figure 4.3). 
 
Unspecific
filtering
• interquartile
range (IQR)
• median 
absolute 
deviation
(MAD)
Statistical test
• Student's t-
test
• Wilcoxon
signed-rank 
test
• Fisher's
exact test
Fold-change
• Fixed values
Pathway
analysis
• Kyoto 
Encyclopedia 
of Genes and 
Genome 
(KEGG)
• Gene 
ontology
(GO)
 
Figure 4.3: Encapsulated R application of genomic data. Steps applied to microarray data (solid 
boxes). The respective alternative procedures are shown in outline boxes below. Difference of expression 
values of comparison groups was set at >1.3-fold and <-1.3-fold. Significant difference of a Student’s t test 
between the comparison groups was set p<0.05 (taken from [139]). 
A B 
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Heat Map analysis of the genomic data obtained (Figure 4.4), reflects gene expression 
values of the different donors upon their different treatment and revealed three major 
results. 
Firstly, each donor displayed different basal gene expression signatures, unexpectedly 
significant. As already indicated by the different HBV antigen levels, HBV infection and 
replication had different impact on gene regulation of each donor, probably due to 
individual physiologic backgrounds. However, this study is focused on gene regulations 
common in all donors, as they might be general happenings in the course of HBV 
infection. Individual, donor specific alterations need to be addressed in a further study.  
Secondly, HBV had only a minor impact on gene regulation of PHHs. This was not 
surprising, as HBV is a noncytopathic virus causing only few gene alterations. 
Progression towards HCC is mainly due to the immunologic reactions as ongoing 
elimination of HBV from infected hepatocytes results in constant inflammation of the liver 
[143] [65]. Nevertheless, those gene aberrations which are triggered by HBV might give 
additional triggers for oncogenic potential of HBV infected cells and the liver. 
Thirdly, HBV infected PHHs remained sensitive towards long term TGF-β treatment. 
Interestingly, TGF-β treatment for 24hrs in HBV infected PHHs resulted mainly in similar 
gene alterations in all donors. However, expression of some genes seemed to be 
influenced by HBV infection. For this study, it was of main interest, whether these 
different expressed genes render the outcome of TGF-β signaling in HBV infected 
PHHs, e.g. from a normal cytostatic response towards a tumorigenic response. 
 
When interpreting the following results, it has to be considered, that microarray analysis 
can yield false-negative results because of its limited sensitivity. HBV proteins might 
modulate other genes and it is possible that the modulation in this microarray study was 
underestimated. Nevertheless, even a relatively small difference in the array analysis 
could be physiologically significant. 
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Figure 4.4: Heat map representation of expression analysis of the microarray data of HBV infected PHHs 
showing all gene expression clusters. The heat map is hierarchically ordered from left to right by whole-
transcriptome expression. 
“HBV/or not TGF-β (h) _Sample number” 
Donor #1 (Sample number 1-7), donor #2 (Sample number 8-14), donor #3 (Sample number 22-28). 
 
4.1.1.3 HBV has only a minor impact on gene regulation of PHHs 
Current literature shows, that HBV is a noncytopathic virus causing only less aberration 
in gene expression of the host cell [143]. It is thought that HCC development is due to 
the immune system, which tries to eliminate infected hepatocytes, thereby leading to a 
constant inflammation of the liver [144] [145]. However, some infected cells escape the 
immune system due to cellular transformations. These cells may be the beginning of 
HCC development. The first aim of this study was to elucidate common and solid 
influences of HBV infection on TGF-β signaling, which may have an oncogenic potential 
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and might be one reason for HCC development upon HBV infection. To investigate 
general mechanisms of HBV induced HCC, only gene alterations which were identical in 
all three donors were taken into account; donor specific regulations, which might be 
important nonetheless, were disregarded. In compliance with these requirements only 
12 genes were found to be regulated upon HBV infection (Figure 4.5 A). Of these genes, 
10 genes were slightly up- and 2 genes were slightly downregulated. According to the 
literature, most of the regulated genes have already been investigated in the context of 
carcinogenesis. KEGG pathway analysis was performed for the search of ontological 
biological processes. Significantly rendered pathways were defined by statistical tests to 
a contingency table, as described in material and methods. As expected from single 
gene knowledge, most pathways regulated were formally assigned to pathways 
associated to glioma, chronic myeloid leukemia, bladder cancer, melanoma, and 
prostate cancer. 
Note: For understanding and simplicity reasons, I will discuss single genes regulated in 
my analysis right in the results section. A more general discussion of the array results 
will be placed in the discussion section of this thesis. The gene MDM2 is upregulated by 
HBV in PHHs, which is involved in the p53 signaling pathway [146]. p53 signaling 
regulates cell cycle arrest, cell death, cell differentiation, senescence, DNA repair and 
neovascularization [147]; its deregulation can lead to impaired apoptosis and increased 
cell proliferation. The MDM2 protein is a transcription factor, which forms a complex with 
p53. This complex inhibits p53 transcriptional activity with subsequent ubiquitination and 
degradation of p53. A reduction in p53 protein levels results in a downregulation of its 
target gene p21, a negative regulator of cell cycle progression at G1 phase [148]. 
Hence, disruption of p53 signaling pathway by an upregulation of MDM2 has an 
oncogenic potential and can lead to increased proliferation, which was already 
investigated in glioma [149], chronic myeloid leukemia [150], bladder cancer [151], 
melanoma [152], and prostate cancer [153]. 
The most upregulated gene identified in this analysis is Thymidylate synthase (TYMS), 
which encodes the rate limiting enzyme in the production of dTTP, required for DNA 
synthesis [154]. Recently, it has been associated to liver cancer proliferation and 
progression, respectively, and drug resistance [155] [156]. TYMS is induced by the 
transcription factor LSF (Late SV40 Factor). Compared to normal hepatocytes and liver, 
a LSF overexpression was detected in human HCC cell lines and in HCC patients LSF 
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expression levels correlated with the stages and grades of the disease. Stable 
overexpression of LSF in less aggressive Hep3B cells resulted in significant increase in 
proliferation, colony formation, soft agar growth and Matrigel invasion [157].  
The spermatogenesis-associated gene, SPATA18, regulates the quality of mitochondria, 
mediating the repairing or degradation of unhealthy mitochondria [158]; mitochondrial 
dysfunction has been implicated in cancer [159]. In response to mitochondrial damage, 
SPATA18 was recently discovered as a novel transcriptional target of p53 and p63 
[160]; Bornstein et al reported that p63 induces SPATA18 and suggested that p63 can 
compensate for a loss of p53 activity due to their homology. Since p53 signaling might 
be impaired in HBV infected PHHs, cell homeostasis might be maintained by p63. 
 
 
HBV vs Ø 
Gene log2 
TYMS 0,58439 
PGA5 0,53731 
SPATA18 0,50189 
ARVP6125 0,45511 
DDB2 0,44591 
CYGB 0,44422 
MDM2 0,43708 
LOC286359 0,42086 
CNGA3 0,40719 
GPR109B 0,39675 
ABCB11 -0,42879 
SNORD116-21 -0,59567 
 
 
Figure 4.5: Gene regulation upon HBV infection common in all donors. (A) List of genes regulated 
upon HBV infection. Values are given in log2. (B) Pathways regulated upon HBV infection. 
 
4.1.1.4 HBV infection decreased the number of TGF-β regulated target 
genes in PHHs 
As it was shown before, that HBV infection influences TGF-β signaling [88] [89], I was 
now interested how HBV infection changes TGF-β dependent gene transcription in 
detail. Comparison of the total number of genes regulated in the microarray analysis 
described above revealed differential regulation of only a few genes: HBV infected 
hepatocytes versus uninfected hepatocytes after 1h (20 genes in uninfected PHHs vs 7 
A B 
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genes in HBV infected PHHs) and after 24hrs (501 genes in uninfected PHHs vs 213 
genes in HBV infected PHHs) TGF-β treatment (Figure 4.6). In total, 1h TGF-β treatment 
regulated around 28 genes in uninfected PHHs and 15 genes in HBV infected PHHs. 
After 24hrs TGF-β treatment, 1566 genes were regulated in uninfected PHHs versus 
1278 genes in HBV infected PHHs. This indicates that HBV reduced the impact of TGF-
β on cell signaling. 
  
  
 
Figure 4.6: Number of TGF-β regulated genes. Amount of upregulated genes in uninfected or HBV 
infected PHHs upon TGF-β treatment (5ng/ml) for (A) 1h and (B) 24hrs. Amount of downregulated genes 
in uninfected or HBV infected PHHs upon TGF-β treatment (5ng/ml) for (C) 1h and (D) 24hrs. 
 
4.1.1.5 HBV infection inhibits regulation of the TGF-β signaling pathway in 
PHHs after 1h TGF-β treatment 
As just described, HBV infection of PHHs reduced the total number of TGF-β regulated 
target genes. As it was shown before, that HBx protein was able to block TGF-β induced 
apoptosis in Hep3B cells [89], I next analyzed which genes were differentially regulated 
after HBV infection of TGF-β treated PHHs and whether these can be assigned to 
cytostatic or tumorigenic TGF-β effects. 
After 1h treatment typical early TGF-β target genes, like negative feedback inhibitor 
Smad7, plasminogen activator inhibitor PAI-1 (Serpine1), the cell cycle arrest protein 
A 
B 
C 
D 
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p21 (CDKN1A), or the DNA-binding protein inhibitor Id-1 (ID1) were found to be 
upregulated in uninfected PHHs (Figure 4.7 A). Interestingly, upregulation of these 
typical TGF-β target genes was not found in HBV infected PHHs (Figure 4.7 B). In HBV 
infected PHHs, only 4 genes were upregulated (PPP1R3B, GUSBL1, NAT8, CEBPB) 
and 3 genes were downregulated (LOC100506959, RPL7A, MIR122). 
CEBPB (CCAAT/enhancer-binding protein beta) is a transcription factor and involved in 
regulation of immune and inflammatory responses. In detail, it was reported to bind to 
the IL-1 response element in the IL-6 gene, to regulatory regions of several acute-phase 
and cytokine genes, and to the promoter of the collagen type I gene [161] [162]. Further, 
it was reported that CEBPB is involved in the transcription of HBV genes [163] [164].  Xu 
et al. investigated the role of TGF-β in the survival of the myelo-monocytic leukemia cell 
line U937 co-cultured with bone marrow (BM)-derived mesenchymal stem cells (MSC). 
TGF-β inhibited spontaneous and cytarabine-induced apoptosis in U937 cells, increased 
pro-survival phosphorylation of Akt, and induced significant upregulation of CEBPB gene 
and protein expression. Although, the observations of Xu et al are obtained in a different 
cellular setup, their results may suggest a novel role of CEBPB in TGF-β induced cell 
survival arguing for its tumorigenic potential [165]. 
The PPP1R3B gene encodes the catalytic subunit of the serine/ threonine phosphatase, 
protein phosphatase-1 (PP-1), which is involved in regulation of hepatic glycogen 
metabolism [166]. TGF-β has been shown to stimulate the motility of endothelial cells, 
keratinocytes, fibroblasts, as well as cancer cells [167] [168]. Walsh et al. reported that 
endothelial cell motility is induced by TGF-β in a PP-1 dependent manner. Although 
these investigations of Walsh et al. have been performed in endothelial cells, it might be 
true for other cell types responsive for TGF-β induced motility [169]. 
MIR122 downregulation was recently reported to enhance interferon-α signaling in the 
liver through regulation of SOCS3 promoter methylation [170]. Interferon-α is a cell 
response after recognition of viral or bacterial nucleic acids. 
Regulated genes which were identified in both, uninfected and HBV infected PHHs had 
similar expression levels (Figure 4.7 C). Among these genes were typical TGF-β target 
genes like GADD45B, BHLHE40, and RND1. GADD45B is induced upon environmental 
stress and is an effector of TGF-β induced apoptosis [171]. BHLHE40 is involved in the 
regulation of apoptosis and cell proliferation and was recently discovered to play a 
promotive role in TGF-β induced EMT [172]. RND1, a member of the Rho GTPase 
family, regulates the organization of the actin cytoskeleton in response to TGF-β [173]. 
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Ø (1h TGF-β) 
Gene Ø 
KLF10 1,5285 
SMAD7 1,5213 
SERPINE1 1,4553 
HES1 1,2280 
ID1 1,1690 
ANGPTL4 0,9867 
ELF3 0,9205 
SLC25A25 0,8804 
SIK1 0,8356 
HAMP 0,7639 
ADM 0,7127 
EFNA1 0,6356 
HMOX1 0,6178 
CEBPA 0,5982 
MIDN 0,5823 
CYR61 0,4704 
CDKN1A 0,4630 
ARRDC2 0,4546 
 
 
 
 
HBV (1h TGF-β) 
Gene HBV 
PPP1R3B 0,5585 
GUSBL1 0,5498 
NAT8 0,4613 
CEBPB 0,3936 
LOC100506959 -0,4449 
RPL7A -0,4938 
MIR122 -0,7580 
overlay of genes (1h TGF-β) 
Gene Ø HBV 
BHLHE40 1,2664 1,0914 
DDIT4 1,8258 1,6785 
DUSP1 0,7954 0,6785 
GADD45B 1,5872 1,4734 
GADD45G 0,9618 0,9324 
RND1 0,6897 0,6737 
TRIB1 0,4325 0,3996 
ZFP36 1,0061 0,9251 
 
Figure 4.7: Gene regulation upon 1h TGF-β. Regulated genes in (A) uninfected (Ø) and (B) HBV 
infected PHHs after 1h TGF-β treatment (5ng/ml). (C) Shows the genes which were regulated in both 
uninfected and HBV infected PHHs. All values are given in log2. 
 
To assign deregulated genes in the context of cell signaling pathways, KEGG pathway 
analysis was performed, and significantly rendered pathways were defined by statistical 
tests to a contingency table, as described in material and methods. TGF-β treatment for 
1h of uninfected PHHs induced the regulation of pathways involved in metabolism, like 
porphyrin and chlorophyll metabolism, and pathways involved in development, like axon 
guidance (Figure 4.8). Interestingly, TGF-β treatment led to the regulation of the TGF-β 
signaling pathway in uninfected PHHs only, but not in HBV infected PHHs. In contrast, in 
HBV infected hepatocytes p53 and mTOR signaling pathway were activated, the latter 
one being a downstream target of Akt survival pathway. Although, several pathways 
associated to cancer were regulated in uninfected PHHs upon 1h TGF-β, these 
pathways were not regulated upon 24hrs TGF-β treatment anymore (Figure 4.11). 
A B 
C 
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upregulated downregulated upregulated downregulated
Cell Cycle 3 0 Cell Cycle 2 0
MAPK signaling pathway 3 0 MAPK signaling pathway 3 0
TGF-β signaling pathway 2 0 p53 signaling pathway 2 0
Axon guidance 2 0 mTOR signaling pathway 1 0
Maturity onset diabetes of the young 1 0 Circadian rhythm - mammal 1 0
Glioma 1 0
Chronic myeloid leukemia 1 0
Acute myeloid leukemia 1 0
Bladder cancer 1 0
Circadian rythm - mammal 1 0
Melanoma 1 0
Porphyrin and chlorophyll metabolism 1 0
1h TGF-β (5ng/ml)
uninfected PHHs HBV-infected PHHs
Number of genes Number of genes
Pathway Pathway
 
Figure 4.8: Pathway regulation upon 1h TGF-β. List of significantly regulated pathways upon 1h TGF-β 
treatment (5ng/ml) of uninfected and HBV-infected PHHs. Signaling pathways only found in either group 
are highlighted in red. 
 
4.1.1.6 HBV infection inhibits regulation of the TGF-β signaling pathway in 
PHHs after 24hrs TGF-β treatment 
Differential expression of the 20 most upregulated genes upon TGF-β treatment for 
24hrs in uninfected and HBV-infected PHHs, as well as genes found to be upregulated 
in both, are listed in Figure 4.9. The 20 most downregulated genes are listed in Figure 
4.10.  
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Ø up (24h TGF-β) 
Gene Ø 
ATF5 1,0410 
RDH16 0,9999 
HNF1B 0,8874 
JMJD1C 0,8544 
NA 0,8303 
GRHL1 0,7940 
MEGF6 0,7777 
CLDN14 0,7585 
BTBD11 0,7421 
TMPRSS9 0,7382 
TBX15 0,7168 
LOC338799 0,7079 
ENKUR 0,6962 
VSIG10L 0,6827 
DGAT2 0,6718 
SLC7A1 0,6680 
RNU2-2 0,6517 
G3BP2 0,6478 
RAP1GAP 0,6237 
NEDD9 0,6182 
 
HBV up (24h TGF-β) 
Gene HBV 
CRYAB 1,2742 
TLE2 1,2506 
IER3 1,1104 
TGFB2 1,1063 
ARHGEF5 1,0614 
GLIPR1 1,0453 
HMOX1 1,0052 
HSD11B2 0,9977 
SPON2 0,9972 
LIMCH1 0,9668 
HAL 0,9611 
C5orf24 0,9075 
SH2D4A 0,8746 
KIAA1147 0,8604 
ADCY5 0,7497 
GPER 0,7489 
LOC402778 0,7285 
MSN 0,6974 
MAFK 0,6907 
ALOX5 0,6888 
overlap up (24h TGF-β) 
Gene Ø HBV 
FAM20A 0,3834 0,4070 
ATP13A2 0,3857 0,4196 
LIMS1 0,3874 0,3848 
TOR1B 0,3891 0,5027 
STK38 0,3949 0,4177 
KIAA1804 0,3976 0,3983 
DBI 0,3976 0,4196 
FAM102B 0,3981 0,6108 
TJP1 0,4000 0,4557 
HIVEP2 0,4002 0,4979 
ARID5A 0,4037 0,3852 
RNFT1 0,4079 0,7694 
ARID2 0,4106 0,4172 
FAM113B 0,4114 0,4720 
WWC3 0,4153 0,3853 
REEP3 0,4242 0,4512 
LYSMD4 0,4245 0,4708 
SLC30A1 0,4257 0,4781 
CDC34 0,4266 0,4056 
MVD 0,4273 0,4182 
 
Figure 4.9: Upregulated genes upon 24h TGF-β. List of the 20 most upregulated genes in (A) 
uninfected (Ø) and (B) HBV infected PHHs after 24hrs TGF-β treatment (5ng/ml). (C) Genes which were 
upregulated in both uninfected and HBV-infected PHHs. All values are given in log2. 
 
 
 
 
 
 
 
 
 
A B C 
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Ø down (24h TGF-β) 
Gene Ø 
CYP7A1 -2,9241 
SLC2A14 -1,3274 
GPRC5B -1,2700 
SLC6A12 -1,2681 
KLF15 -1,2610 
UGT1A9 -1,1384 
CBS -1,1087 
LIPG -1,1017 
GLYCTK -1,0453 
ASB13 -1,0175 
HSD17B13 -0,9834 
LAMA3 -0,9792 
AKR1D1 -0,8275 
C14orf105 -0,8033 
SEPX1 -0,7850 
TCEA2 -0,7648 
PCYT2 -0,7502 
DEFB1 -0,7488 
MYRIP -0,7274 
AHSG -0,7104 
 
 
HBV down (24h TGF-β) 
Gene HBV 
GPX2 -1,1954 
CYP4A11 -1,0598 
SOAT2 -1,0266 
CITED2 -1,0214 
ADRA1A -0,9596 
FSTL1 -0,8815 
CYP2A7 -0,8156 
RSC1A1 -0,8084 
FLVCR2 -0,7886 
ELF3 -0,7857 
TMEM140 -0,7807 
RORC -0,7585 
MYC -0,7350 
ADCK3 -0,7177 
ACSM5 -0,7065 
BTN3A1 -0,6977 
HSD17B2 -0,6675 
TBC1D8 -0,6341 
UGT1A10 -0,6282 
CNNM1 -0,6259 
overlap down (24h TGF-β) 
Gene Ø HBV 
SULT2A1 -2,6561 -2,5265 
HLF -2,3367 -2,4098 
TDO2 -2,2251 -2,2700 
GYS2 -2,2206 -1,8480 
FABP1 -2,1885 -1,9388 
SLC6A1 -2,0948 -2,0833 
PCK1 -2,0395 -1,9637 
ACOT12 -2,0344 -1,7925 
GNMT -2,0311 -1,7818 
ADH1B -2,0177 -2,1255 
BBOX1 -1,8964 -1,7890 
PAH -1,8528 -1,9035 
CREB3L3 -1,8413 -1,9998 
LBP -1,8360 -1,7871 
ADH1A -1,7776 -1,7384 
HAO1 -1,7733 -1,6251 
AKR1C4 -1,7620 -1,5969 
VNN1 -1,7396 -1,7904 
CYP2E1 -1,7396 -1,7313 
BHMT -1,7386 -1,7249 
 
Figure 4.10: Downregulated genes upon 24h TGF-β. List of the 20 most downregulated genes in (A) 
uninfected (Ø) and (B) HBV infected PHHs after 24hrs TGF-β treatment (5ng/ml). (C) Shows the genes 
which were downregulated in both uninfected and HBV-infected PHHs. All values are given in log2. 
 
As they are so many, regulated genes upon 24h TGF-β treatment cannot be discussed 
in detail here. Therefore, special attention is laid on the analysis of regulated signaling 
pathways. Upon 24hrs TGF-β treatment in HBV infected PHHs, only a few metabolic 
pathways, but more cancer associated pathways were regulated (Figure 4.11). 
According to the ontology of KEGG pathway analysis, this includes e.g. colorectal 
cancer, bladder cancer, melanoma, acute myeloid leukemia, and basal cell carcinoma 
among others. Further, insulin signaling pathway, an important pathway for cell 
homeostasis, was regulated in HBV infected PHHs. Disturbance of insulin signaling in 
concert with HBV infection has already been reported [174] [175] [176]. As described for 
1h TGF-β treatment results, the TGF-β signaling pathway was only regulated in 
uninfected PHHs after 24hrs of TGF-β treatment, but not in HBV infected PHHs. This 
shows that TGF-β signaling pathway sensitivity might be impaired in hepatocytes upon 
HBV infection. 
A B C 
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upregulated downregulated upregulated downregulated
Acute myeloid leukemia 7 0 ABC transporters 6 3
Adherens junction 10 5 Acute myeloid leukemia 7 0
Adipocytokine signaling pathway 3 7 Adherens junction 8 6
Alanine, aspartate and glutamate metabolism 2 8 Adipocytokine signaling pathway 4 6
Aldosterone-regulated sodium reabsorption 3 3 Aldosterone-regulated sodium reabsorption 5 3
alpha-Linolenic acid metabolism 3 2 Arachidonic acid metabolism 3 7
Arginine and proline metabolism 2 13 Arginine and proline metabolism 2 10
Ascorbate and aldarate metabolism 0 9 Ascorbate and aldarate metabolism 0 8
Biosynthesis of unsaturated fatty acids 6 3 Axon guidance 13 4
Bladder cancer 5 1 Base excision repair 2 5
Butanoate metabolism 0 8 beta-Alanine metabolism 0 5
Caffeine metabolism 0 4 Bladder cancer 7 1
Drug metabolism - other enzymes 2 7 Butanoate metabolism 1 7
ErbB signaling pathway 9 4 Caffeine metabolism 0 5
Ether lipid metabolism 2 6 Drug metabolism - other enzymes 2 8
Fat digestion and absorption 5 3 ErbB signaling pathway 10 4
Glycerolipid metabolism 4 10 Fat digestion and absorption 4 2
Glycerophospholipid metabolism 5 11 Glioma 4 1
Glycolysis / Gluconeogenesis 1 13 Glycerolipid metabolism 4 6
Glycosaminoglycan biosynthesis - keratan sulfate 1 4 Glycerophospholipid metabolism 6 6
GnRH signaling pathway 4 3 Glycolysis / Gluconeogenesis 1 12
Lysine degradation 3 10 Glycosaminoglycan biosynthesis - keratan sulfate 2 2
Mismatch repair 1 4 Glyoxylate and dicarboxylate metabolism 2 6
Nitrogen metabolism 0 7 GnRH signaling pathway 4 3
One carbon pool by folate 1 4 Insulin signaling pathway 11 6
Other types of O-glycan biosynthesis 5 8 Long-term depression 3 2
Pancreatic cancer 4 2 Lysine degradation 2 6
Pantothenate and CoA biosynthesis 0 5 MAPK signaling pathway 17 13
Pentose and glucuronate interconversions 0 10 Mucin type O-Glycan biosynthesis 3 2
Phenylalanine metabolism 0 7 Nitrogen metabolism 1 6
Propanoate metabolism 0 7 One carbon pool by folate 1 4
Purine metabolism 6 18 Osteoclast differentiation 8 7
Pyruvate metabolism 2 9 Other types of O-glycan biosynthesis 4 7
Retinol metabolism 1 6 Pancreatic cancer 6 2
Starch and sucrose metabolism 0 11 Pantothenate and CoA biosynthesis 0 6
Sulfur metabolism 0 4 Pathways in cancer 22 5
Synthesis and degradation of ketone bodies 1 3 Pentose and glucuronate interconversions 0 9
T cell receptor signaling pathway 7 3 Phenylalanine metabolism 0 7
TGF-β signaling pathway 16 3 Phototransduction 1 2
Ubiquinone and other terpenoid-quinone biosynthesis 0 3 Primary bile acid biosynthesis 1 5
VEGF signaling pathway 5 5 Propanoate metabolism 1 7
Vitamin B6 metabolism 1 2 Prostate cancer 7 1
Proximal tubule bicarbonate reclamation 1 4
Pyruvate metabolism 3 7
Renal cell carcinoma 6 0
Starch and sucrose metabolism 0 11
Terpenoid backbone biosynthesis 4 0
Vascular smooth muscle contraction 6 8
Vitamin B6 metabolism 1 2
Vitamin digestion and absorption 1 4
24h TGF-β (5ng/ml)
uninfected PHHs HBV-infected PHHs
Number of genes Number of genes
Pathway Pathway
 
Figure 4.11: Pathway regulation upon 24h TGF-β. List of significantly regulated pathways upon 24hrs 
TGF-β treatment (5ng/ml) of uninfected and HBV infected PHHs. Signaling pathways only found in either 
group are highlighted in red. 
 
In total, 27 genes related to Cancer Pathways were regulated, of which 22 genes were 
up- and 5 genes were downregulated (Figure 4.1). The highest upregulated gene was 
EGLN3 and its overexpression was identified in renal cell carcinoma before [180]. E2F3 
a member of the transcription factor family E2F was also found to be upregulated. E2F3 
upregulation is involved in cellular transformation [181]. c-myc, which induces genetic 
instability [182] was downregulated upon HBV infection, confirming the results obtained 
by Ryu et al. 2006 [183]. 
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HBV (24h TGF-β) 
Pathways in Cancer 
upregulated genes downregulated genes 
Gene fold-induction Gene 
fold-
induction 
EGLN3 
ITGAV 
PDGFA 
FGF2 
SMAD3 
CEBPA 
RARA 
RUNX1 
CDKN1A 
FN1 
PPARD 
VEGFA 
ERBB2 
EPAS1 
VEGFB 
LAMA5 
STAT3 
E2F3 
TCEB1 
FZD6 
TGFA 
FOXO1 
3,449 
3,343 
3,124 
3,024 
2,635 
2,308 
2,258 
2,134 
1,996 
1,752 
1,697 
1,682 
1,606 
1,547 
1,499 
1,477 
1,415 
1,390 
1,380 
1,371 
1,345 
1,303 
BIRC3 
MYC 
FZD4 
CDK4 
PLD1 
0,488 
0,601 
0,622 
0,686 
0,708 
Figure 4.12: Regulated genes associated to cancer. List of regulated genes belonging to pathways in 
cancer in HBV infected PHHs upon 24hrs TGF-β treatment (5ng/ml). 
 
In this study, regulation of the TGF-β signaling pathway was abrogated in HBV infected 
PHHs. Interestingly, Smad3, as a member of the canonical TGF-β signaling pathway 
was upregulated by TGF-β in HBV infected PHHs. Honda et al. 2006 performed a 
microarray study comparing tissue of patients with chronic hepatitis B or chronic 
hepatitis C. They identified an upregulation of Smad3 in chronic HBV but independent of 
TGF-β. Honda et al. hypothesized that pro-apoptotic and DNA repair responses are 
predominant upon HBV infection [184]. Microarray results of this study point that pro-
apoptotic TGF-β signaling pathway is abrogated and Smad3 upregulation might be 
associated to another function, e.g. it is thought to play a role in the regulation of 
carcinogenesis, like in prostate cancer, due to regulation of angiogenic molecule 
expression [185]. 
Next, the different significantly regulated signaling pathways were assigned to 
biologically functional categories. In general, HBV infection had a major impact on the 
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cell, highlighted in the broad variety of functional categories affected and the great 
impact towards the outcome of TGF-β treatment. In detail, the assignment revealed, that 
most regulated pathways in uninfected PHHs upon 24hrs TGF-β treatment belonged to 
metabolism processes, like metabolism of cofactors and vitamins, lipid metabolism, 
amino acid metabolism, nucleotide metabolism, and energy metabolism (Figure 4.13); 
whereas less metabolic pathways were regulated in HBV infected PHHs. This suggests 
that HBV deplets cellular resources probably needed for its replication and propagation 
process.  
Funcional Category Pathways Funcional Category Pathways
Amino Acid Metabolism 4 Amino Acid Metabolism 3
Biosynthesis of other secondary metabolites 1 Biosynthesis of other secondary metabolites 1
Cancers 3 Cancers 7
Carbohydrate Metabolism 7 Carbohydrate Metabolism 8
Cell Communication 1 Cell Communication 1
Digestive System 1 Circulatory System 1
Endocrine System 2 Development 1
Energy Metabolism 2 Digestive System 2
Excretory System 1 Endocrine System 3
Glycan Biosynthesis and Metabolism 2 Energy Metabolism 1
Immune System 1 Excretory System 1
Lipid Metabolism 6 Glycan Biosynthesis and Metabolism 2
Metabolism of Cofactors and Vitamins 5 Lipid Metabolism 4
Nucleotide Metabolism 1 Membrane Transport 1
Replication and Repair 1 Metabolism of Cofactors and Vitamins 3
Signal Transduction 3 Metabolism of other Amino Acids 1
Xenobiotics biodegradation and metabolism 1 Metabolism of Trepenoids and Polyketides 1
Nervous System 1
Replication and Repair 1
Sensory System 1
Signal Transduction 2
Xenobiotics biodegradation and metabolism 1
uninfected HBV infected
24h TGF-β (5ng/ml)
 
Figure 4.13: Regulated functional categories upon 24h TGF-β. Amount of pathways regulated within 
the functional categories of uninfected and HBV infected PHHs treated for 24hrs with TGF-β (5ng/ml). 
 
4.1.1.7 HBV infection inhibits Smad3 phosphorylation upon TGF-β 
treatment in PHHs 
The microarray results of this study indicate that HBV impairs the sensitivity of PHHs 
towards exogenous TGF-β stimulation. As suggested by p21 downregulation in TGF-β 
treated HBV infected PHHs compared to uninfected PHHs, HBV might inhibit TGF-β 
induced apoptosis in hepatocytes, probably to assure virus survival. In epithelial cells as 
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haptocytes, cytostatic TGF-β signaling is mainly mediated via the canonical Smad3 
pathway [186]. To validate the hypothesis, that HBV inhibits TGF-β signaling via Smad3, 
PHHs of 3 other donors were infected with HBV or not. One donor displayed an 
impaired phosphorylation of Smad3 upon 48h TGF-β treatment (Figure 4.14). Although 
this was found only once out of three different donors, this finding might support the 
hypothesis, that HBV infection is able to inhibit the activation of TGF-β signaling via 
Smad3, which can lead to decreased apoptosis. 
Availability of PHHs is limited, nevertheless, screening of a greater set of donors is 
urgently needed to elucidate the sigificance of this finding and should be considered for 
further investigations. 
 
 
Figure 4.14: HBV infection inhibits Smad3 phosphorylation in HBV infected PHHs. PHHs were 
infected with HBV or not. Four days post-infection, PHHs were treated with TGF-β for 48hrs. PHHs were 
harvested on day 6 post-infection. Protein lysates were subjected to immunoblot analysis of pSmad3. 
GAPDH served as loading control. 
 
In summary, cDNA microarray of HBV infected PHHs vs. uninfected PHHs revealed that 
HBV is a noncytopathic virus causing few gene aberrations. Secondly, TGF-β treatment 
for either 1h or 24hrs of HBV and uninfected PHHs showed, that the number of TGF-β 
regulated target genes is decreased upon HBV infection. Thirdly, HBV infection was 
able to inhibit TGF-β effects related to regulation of the TGF-β signaling pathway, e.g. 
Smad7 regulation and TGF-β target genes, like p21, which is involved in TGF-β induced 
apoptosis and growth arrest. This was supported by an abrogated Smad3 
phosphorylation in HBV infected hepatocytes upon TGF-β treatment. Fourthly, global 
characteristics of gene expression profiles upon 24hrs TGF-β treatment support the 
hypothesis of current literature, that the process of HBV replication limits cellular 
resources needed for proper metabolism, thereby causing a deregulation of cell 
signaling which can be responsible for cell transformation. 
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4.1.2 Akt deactivation sensitizes HepG2.2.15 cells for TGF-β induced 
apoptosis 
Gene expression analysis presented in this study revealed inhibition of the canonical 
TGF-β signaling pathway by HBV infection confirmed by abrogation of Smad7 induction, 
and the abrogation of p21 induction (Figure 4.7). The latter possibly causes inhibition of 
TGF-β induced apoptosis/ growth arrest. Inhibition of Smad3 phosphorylation in HBV 
infected PHHs (Figure 4.14) supported the hypothesis of an impaired TGF-β signaling. 
To verify these results and analyze its underlying mechanism in more detail, the cell line 
HepG2.2.15 was used. These cells are derived from the parental cell line HepG2, stably 
transfected with a plasmid containing full HBV DNA [67]. As HepG2.2.15 cells produce 
infectious HBV particles, they are able to reveal effects induced by HBV proteins after 
HBV infection. Further, HepG2.2.15 cells present a purified liver cell model, disregarding 
the in vivo effects of other cells of the liver or the immune system. Hence, HepG2.2.15 
cells are a valuable model for investigating the effects of HBV proteins on host cells 
[187]. 
 
4.1.2.1 TGF-β dependent Smad3 transcriptional activity is reduced and 
Smad3 phosphorylation level is more transient 
As described above, HBV infection impaired TGF-β induced gene expression of TGF-β 
signaling components and reduced Smad3 phosphorylation in PHHs. To investigate the 
underlying mechanism, HepG2.2.15 cells and the parental cell line HepG2 were treated 
with TGF-β in a time course from 0 to 24hrs. Smad3 expression levels were equal in 
both cell lines as confirmed by Immunoblot analysis (Figure 4.15). HBV replication 
reduced Smad3 phosphorylation levels from prolonged in HepG2 to transient in 
HepG2.2.15 cells. No changes were seen in Smad2 phosphorylation levels at any time 
points. 
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Figure 4.15: HBV reduced Smad3 phosphorylation levels in HepG2.2.15 cells. HepG2 and 
HepG2.2.15 cells were starved overnight prior to treatment with TGF-β (5ng/ml) for the indicated time 
points. Protein lysates were subjected to immunoblot analysis of pSmad3, Smad3, and pSmad2. Tubulin 
served as loading control. 
 
CAGA reporter assay was performed to investigate the impact of impaired Smad3 
phosphorylation on its transcriptional activity. As expected, reduced Smad3 dependent 
transcriptional activity was detected upon TGF-β treatment in HepG2.2.15 cells 
compared to HepG2 control cells (Figure 4.16) already after 3hrs. 
 
 
 
Figure 4.16: Smad3 transcriptional activity 
is reduced in HepG2.2.15 cells. HepG2 and 
HepG2.2.15 cells were cotransfected with 
plasmids encoding β-Gal and the CAGA 
sequence, respectively, using Lipofectamine 
2000 for 4hrs. Cells were starved overnight 
prior to treatment with TGF-β (5ng/ml) for the 
indicated time points. *p<0.05 and **p<0.02. 
 
4.1.2.2 TGF-β has no impact on cell death 
Microarray results of HBV infected PHHs indicated that stimulated TGF-β signaling and 
Smad3 phosphorylation is impaired. In line one typical TGF-β target gene p21, involved 
in cell cycle arrest, was not induced by TGF-β treatment in HBV infected PHHs. Further, 
Smad3 signaling known to mediate TGF-β induced apoptosis [58], was also impaired in 
HepG2.2.15 cells. These results suggest that TGF-β induced apoptosis might be 
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impaired upon HBV infection. To investigate this hypothesis, HepG2.2.15 cells were 
treated with TGF-β and a LDH assay was performed. TGF-β treatment had no 
significant impact on apoptosis in HepG2.2.15 (Figure 4.17). However, HepG2 cells 
were insensitive towards TGF-β induced apoptosis as well, in line with previous reports 
[129].  
 
 
Figure 4.17: HepG2.2.15 and HepG2 cells 
are insensitive to TGF-β induced apoptosis. 
HepG2 and HepG2.2.15 cells were starved 
overnight prior to treatment with TGF-β 
(5ng/ml) for 24hrs. LDH release was measured 
in the supernatant. ns = not significant 
 
 
4.1.2.3 HBV induced pAkt levels independently of TGF-β 
Although resistance against TGF-β induced apoptosis was monitored in both, HepG2 
and HepG2.2.15, I asked, whether there are different regulation mechanisms 
responsible maybe via different / additional impact of HBV on apoptosis resistance of 
HepG2.2.15 cells. It was reported before, that viruses induce activation of cell survival 
pathways to inhibit death of cells they infect [89] [188] [189] [190] [191]. Accordingly, an 
increase in Akt activation has been reported to be associated with HBV infection [192] 
[193] and pro survival Akt signaling antagonizes apoptotic pathways like TGF-β signaling 
[194]. Therefore, Akt activation was analyzed for its capability to influence the resistance 
of HepG2 and/or HepG2.2.15 cells against TGF-β induced apoptosis. 
Investigation of Akt phosphorylation by immunoblot analysis revealed higher Akt 
activation in HepG2.2.15 cells replicating HBV compared to HepG2 cells (Figure 4.18). 
However, Akt phosphorylation was independent of TGF-β treatment.  
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Figure 4.18: HBV induced pAkt independent of 
TGF-β. HepG2 and HepG2.2.15 cells were starved 
overnight prior to treatment with TGF-β (5ng/ml) for 
1h and 24hrs. Protein lysates were subjected to 
Immunoblot analysis of pAkt and Akt. Tubulin 
served as loading control. 
 
4.1.2.4 Akt deactivation sensitizes HepG2.2.15 cells for TGF-β induced 
apoptosis 
To investigate whether the elevated levels of phosphorylated Akt are responsible for the 
inhibition of TGF-β induced apoptosis in HepG2.2.15 cells, cells were treated with Akt 
inhibitor LY294002 (20µM) for 2hrs prior to TGF-β treatment for 24hrs. To proof proper 
inhibition of Akt inhibitor LY294002, cell lysates were investigated by Immunoblot 
analysis, showing that Akt phosphorylation was completely abolished by usage of 
LY294002 (Figure 4.19 A). Upon deactivation of Akt and concomitant TGF-β treatment, 
HepG2.2.15 showed increased cell death (Figure 4.19 B) as measured by LDH assay. 
In contrast, HepG2 cells were completely insensitive towards TGF-β induced cell death 
after treatment with Akt inhibitor. Treatment of HepG2.2.15 cells with either TGF-β or Akt 
inhibitor alone had no significant impact on cell death. In line, PARP cleavage showed 
that treatment of HepG2.2.15 cells with Akt inhibitor sensitized those for TGF-β induced 
apoptosis.  
In order to test whether autocrine TGF-β effects would have any impact on apoptosis or 
Smad phosphorylation, type I TGF-β receptor inhibitor SB431542 (5µM) was used. 
However, there was no difference in apoptosis or Smad3 phosphorylation compared to 
DMSO treated cells, indicating no significant role of autocrine TGF-β signaling in this 
context.  
Overall, basal Smad3 phosphorylation levels in HepG2.2.15 cells were low compared to 
HepG2 cells. 
This result suggests that HBV infection increases Akt activation, which in turn might be 
responsible for impaired responsiveness towards TGF-β induced apoptosis in the cell 
line.  
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Figure 4.19: Akt deactivation sensitizes HepG2.2.15 cells for TGF-β induced apoptosis. HepG2 and 
HepG2.2.15 cells were starved overnight and treated for 2h with Akt inhibitor LY294002 (20µM) or with 
type I TGF-β receptor inhibitor SB431542 (5µM) prior to treatment with TGF-β (5ng/ml) for 24hrs. (A) LDH 
release was measured in the supernatant. (B) Protein lysates were subjected to Immunoblot analysis of 
PARP, Smad3, and pAkt. Tubulin served as loading control. **p<0.02 
 
Taken together these results suggest that regulation of the crosstalk between TGF-β 
signaling, Akt signaling and other proapoptotic and pro survival pathways is influenced 
by HBV infection. However, the exact interplay and all players remain to be elucidated 
 
4.1.2.5 Smad7 overexpression does not abrogate TGF-β induced apoptosis 
upon Akt deactivation in HepG2.2.15 
Canonical Smad signaling is mainly responsible for mediation of TGF-β induced 
apoptosis [40] [41] [43]. As Smad3 phosphorylation and activation is reduced in HBV 
replicating cells, TGF-β induced apoptosis after Akt inhibition might be mediated by 
Smad independent signaling. To proof this hypothesis, the negative feedback inhibitor of 
canonical TGF-β signaling Smad7, was overexpressed by adenovirus infection. Smad7 
overexpression was confirmed by Immunoblot analysis and reduced Smad3 
phosphorylation proved functionality of overexpressed Smad7 (Figure 4.20 A). 
Adenovirus infection in combination with DMSO or TGF-β treatment had no impact on 
cell death in HepG2 and HepG2.2.15 cells (Figure 4.20 B). However, adenovirus 
infection in combination with inhibitor treatment had an impact on cell death in 
HepG2.2.15 cells observed by an increase in LDH release, but there was no increase in 
cleaved PARP. Upon Smad7 overexpression and Akt inhibition no decrease in TGF-β 
induced apoptosis could be observed.  
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In summary, Smad7 overexpression by adenovirus infection suggests, Smad 
independent TGF-β induced apoptosis upon Akt inhibition. However, as an effect of 
control adenovirus infection had significant impact on apoptosis in LY294002 treated 
cells this question needs to be analyzed by different means to allow conclusive 
interpretation. Therefore, knock-down of Smad3 was used as an alternative approach to 
address this question. 
 
 
 
 
 
Figure 4.20: Smad7 overexpression had no decreasing effect on TGF-β induced apoptosis upon 
Akt deactivation. HepG2 and HepG2.2.15 cells were transduced with AdLacZ or AdSmad7 for 2hrs and 
kept on starvation medium for 48hrs. Cells were treated with Akt inhibitor LY294002 (20µM) for 2hrs prior 
to treatment with TGF-β (5ng/ml) for 24hrs. (A) LDH release was measured in the supernatant. (B) Protein 
lysates were subjected to Immunoblot analysis of PARP, Smad3, and Smad7. Tubulin served as loading 
control. ns = not significant. *p<0.02 
 
4.1.2.6 TGF-β induced apoptosis upon Akt deactivation is potentially 
Smad3 independent in HepG2.2.15 cells 
To clarify, whether TGF-β induced apoptosis in HepG2.2.15 cells treated with Akt 
inhibitor is independent of Smad signaling, Smad3, the main driver mediating TGF-β 
induced apoptosis in epithelial cells [58] [59], was downregulated by RNA interference. 
Due to the low detection specificity of the Smad3 antibody available, downregulation of 
Smad3 was investigated indirectly by a downregulation of phospho-Smad1/3 (Figure 
4.21 A). In contrast to adenoviral control infection, control siRNA did not induce 
apoptosis of Akt inhibitor treated cells allowing straight forward interpretation of the 
results obtained. Smad3 downregulation did not reduce apoptosis in LY294002 and 
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TGF-β treated HepG2.2.15 as measured by LDH assay, indicating that TGF-β induced 
apoptosis upon Akt deactivation is independent of Smad3 signaling (Figure 4.21 B). 
However, an increase of PARP cleavage upon Smad3 downregulation and TGF-β 
treatment in HepG2.2.15 cells was demonstrated. These different results might be 
explained by different sensitivity of LDH assay and PARP cleavage assay. Further, LDH 
measures apoptosis and secondary necrosis, while PARP is a more specific marker for 
caspase mediated apoptosis. 
In summary, the results shown do not allow a final interpretation of the role of Smad3 for 
TGF-β mediated apoptosis in LY294002 treated HepG2.2.15 cells. 
 
 
 
 
Figure 4.21: Downregulation of Smad3 has no decreasing effect on TGF-β induced apoptosis upon 
Akt deactivation. HepG2 and HepG2.2.15 cells were transfected with siControl or siSmad3 for 6hrs, 
respectively, and starved for 48hrs. Cells were treated with Akt inhibitor LY294002 (20µM) for 2hrs prior to 
treatment with TGF-β (5ng/ml) for 24hrs. (A) LDH release was measured in the supernatant. (B) Protein 
lysates were subjected to immunoblot analysis of PARP, pAkt, and Smad3 (B). Tubulin served as loading 
control. ns = not significant. 
 
4.1.2.7 Smad3 overexpression does not increase TGF-β induced apoptosis 
upon Akt deactivation in HepG2.2.15 cells 
It was reported before by Conery et al. that Akt is able to interact with unphosphorylated 
Smad3 in the cytoplasm, preventing its phosphorylation and translocation to the 
nucleus, thereby inhibiting TGF-β induced apoptosis in Hep3B cells [54]. This 
observation raised the question, whether the elevated Akt activation in HepG2.2.15 cells 
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might inhibit Smad3 signaling by this mechanism in HepG2.2.15 cells. It was analyzed, 
whether Smad3 overexpression can rescue functional Smad3 signaling and whether 
concomitant Akt inhibition can elevate TGF-β induced apoptosis in HepG2.2.15 cells. 
Smad3 was overexpressed as confirmed by Immunoblot analysis (Figure 4.22 A) (Note: 
As ectopic expressed Smad3 has a flag-tag, its molecular weight is heavier and runs 
higher on the immunoblot as endogenous Smad3). Although the amount of adenovirus 
used for Smad3 overexpression was equal in HepG2 and HepG2.2.15 cells, expression 
levels were higher in HepG2 cells. This might be due to interference of HBV and 
adenovirus in HepG2.2.15 cells. However, nothing has been reported towards this 
observation before. An increase in Smad3 phosphorylation level upon treatment with 
LY294002 and TGF-β, compared to treatment with TGF-β alone was observed in 
HepG2 and HepG2.2.15 cells. This may confirm the results of Conery et al., described 
above, that Akt prevents phosphorylation of Smad3. Adenovirus infection had no impact 
on LDH release in HepG2 and HepG2.2.15 cells allowing straight forward interpretation 
of the results obtained (Figure 4.22 B). Smad3 overexpression and Akt inhibition had no 
increasing effect on TGF-β induced apoptosis in HepG2 and HepG2.2.15 cells as 
determined by LDH release. Results observed on PARP cleavage nicely fit to the results 
of LDH assay. PARP cleavage and low levels of total PARP were observed upon 
treatment with TGF-β and Akt inhibitor in HepG2.2.15 cells, but were independent of 
Smad3 overexpression. In contrast to purified Adenovirus, which was used for Smad7 
overexpression, adenovirus soup, which was used for Smad3 overexpression, had no 
impact on apoptosis in combination with Akt inhibitor. 
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Figure 4.22: Smad3 overexpression does not increase TGF-β induced apoptosis upon Akt 
deactivation. HepG2 and HepG2.2.15 cells were transduced with AdLacZ or AdSmad3 for 2hrs, 
respectively, and starved for 48hrs. Cells were treated with Akt inhibitor LY294002 (20µM) for 2hrs prior to 
treatment with TGF-β (5ng/ml) for 24hrs. (A) LDH release was measured in the supernatant. (B) Protein 
lysates were subjected to immunoblot analysis of PARP, pSmad3, and Smad3 (B). Tubulin served as 
loading control. ns = not significant. 
 
In summary, Smad3 downregulation and Smad3 overexpression had no significant 
impact on LDH release in TGF-β induced apoptosis upon Akt deactivation. However, 
PARP cleavage revealed contradictory results compared to LDH assay after Smad3 
knock down and TGF-β treatment. 
Taken together, results obtained by Smad7 overexpression, Samd3 overexpression and 
Smad3 knockdown suggest that TGF-β mediated apoptosis is probably independent of 
Smad3 signaling after Akt inhibition in HBV replicating HepG2.2.15 cells. 
 
4.1.2.8 SB203580 reduces TGF-β induced apoptosis upon Akt deactivation 
in HepG2.2.15 cells 
It has been reported before, that TGF-β induced apoptosis can be mediated 
independent of Smad signaling by MAPKs, JNK, and p38 signaling pathways [49], [50], 
[51] [52]. Since TGF-β induced apoptosis upon Akt inhibition was probably independent 
of Smad3 signaling in HepG2.2.15 cells, impact of these crosstalking pathways was 
analyzed. Cells were treated with different inhibitors of these pathways: PD98059 
(20µM) for MEK1 inhibition, U0126 (10µM) for MEK1/2 inhibition, SP600125 (20µM) for 
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JNK inhibition and SB203580 (5µM) for p38 inhibition. Treatment with the inhibitors 
alone did not induce cell death, except for U0126 in HepG2 cells (Figure 4.23). Inhibition 
of MAPK pathway by either PD98059 or U0126 strongly induced cell death in HepG2 
cells upon TGF-β treatment, but only moderately in HepG2.2.15 cells. Concomitant 
treatment with Akt inhibitor, MAPK pathway inhibitors, and TGF-β, induced strong cell 
death in both, HepG2 and HepG2.2.15 cells. This suggests that in cells not replicating 
HBV, activation of MAPK pathway is highly needed to counteract TGF-β induced 
apoptosis. 
 
 
Figure 4.23: Signaling pathway involved in the mediation of TGF-β induced apoptosis upon Akt 
deactivation. HepG2 and HepG2.2.15 cells were starved overnight and treated for 2h with Akt inhibitor 
LY294002 (20µM), MEK1 inhibitor PD98059 (20µM), MEK1/2 inhibitor U0126 (10µM), JNK inhibitor 
SP600125 (20µM), and p38 inhibitor SB203580 (5µM) prior to treatment with TGF-β (5ng/ml) for 24hrs. 
LDH release was measured in the supernatant. 
 
Treatment with JNK inhibitor did not change apoptotic levels in HepG2 nor in 
HepG2.2.15 cells. Treatment with p38 inhibitor SB203580 (5µM) decreased TGF-β 
induced apoptosis upon Akt deactivation in HepG2.2.15 cells (Figure 4.23 and 4.24 A). 
No impact on LDH release was observed in HepG2 cells upon treatment with SB203580 
and Akt inhibitor and TGF-β, respectively (Figure 4.23 and 4.24 A). In summary, only 
usage of inhibitor SB203580 could reduce TGF-β induced apoptosis upon Akt inhibition 
in HepG2.2.15 cells. 
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Immunoblot analysis of protein lysates revealed that treatment with SB203580 reduced 
Smad3 phosphorylation levels in both, HepG2 and HepG2.2.15 cells (Figure 4.24 B). 
Strong PARP cleavage was investigated in HepG2.2.15 samples treated with Akt 
inhibitor and TGF-β, but were reduced upon additional treatment with SB203580. 
Interestingly, reduced p38 activation by SB203580 was not detectable. Specificity of p-
p38 antibody was proven in Huh7 lysate (Figure 4.24 C) suggesting low levels of p-p38 
in HepG2 and HepG2.2.15 below antibodies sensitivity. p38 expression levels were 
equal in both cell lines independent of treatment. 
 
 
 
 
Figure 4.24: SB203580 reduces TGF-β 
induced apoptosis upon Akt deactivation in 
HepG2.2.15 cells. HepG2 and HepG2.2.15 cells 
were starved overnight and treated for 2h with 
Akt inhibitor LY294002 (20µM) and p38 inhibitor 
SB203580 (5µM) prior to treatment with TGF-β 
(5ng/ml) for 24hrs. (A) LDH release was 
measured in the supernatant. (B) Protein lysates 
were subjected to immunoblot analysis of PARP, 
pSmad3, p-p38, and p38. (C) Cells were starved 
overnight prior to treatment with TGF-β (5ng/ml). 
Protein lysates were subjected to immunoblot 
analysis of p-p38 levels. Lysate of Huh7 cells 
served as positive control (PC). Tubulin served 
as loading control. 
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4.1.2.9 Knock-down of p38 does not impair TGF-β induced apoptosis upon 
Akt inhibition 
In line with my result above, it was reported recently [195], that HepG2.2.15 cells do not 
show basal p38 phosphorylation. Hence, the impact of SB203580 on the reduction of 
TGF-β induced apoptosis upon Akt deactivation in this study is probably not caused by 
p38 activation inhibition. To clarify this, cells were transduced with lentivirus carrying 
siRNA against p38. LDH assay revealed, that there was no reduction in cell death as 
observed upon usage of SB203580 (Figure 4.25 A). However, as a complete 
downregulation of p38 was not achieved by siRNA repetition of the experiments (Figure 
4.25 B), for future experiments usage of a stable knock out cell line would give more 
information. Furthermore, it has to be considered, that the SB203580 charge used is not 
specific for p38 as indicated. 
In summary the results presented here do not delineate p38 involvement in TGF-β 
dependent apoptosis of LY294002 treated HepG2.2.15 cells. 
 
 
 
Figure 4.25: p38 knock-down does not impair TGF-β induced apoptosis in HepG2.2.15 cells. 
HepG2.2.15 cells were transduced with AdLacZ or AdSmad3 for 2hrs, respectively, and starved for 48hrs. 
Cells were treated with Akt inhibitor LY294002 (20µM) for 2hrs prior to treatment with TGF-β (5ng/ml) for 
24hrs. (A) LDH release was measured in the supernatant. (B) Protein lysates were subjected to 
immunoblot analysis of PARP, pSmad3, and Smad3 (B). Tubulin served as loading control. 
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4.1.2.10 SB203580 has no negative influence on HBV replication 
Viral infection and replication is reported to induce cell stress which might lead to an 
increase in cell apoptosis [196]. Reducing HBV replication may improve cell stability and 
viability, turning them more resistant against usage of pro-apoptotic agents like TGF-β. 
In this study, p38 inhibitor SB203580 decreased TGF-β induced apoptosis upon Akt 
inhibition in HepG2.2.15 cells. However, a decrease in p38 activation could not be 
proven. Furthermore, knockdown of p38 had no comparable effect. This raised the 
question, whether SB203580 has a negative impact on HBV replication itself, which in 
turn might be responsible for the decrease of TGF-β induced apoptosis upon Akt 
activation in HepG2.2.15 cells. To investigate this hypothesis, cells were treated with 
SB203580 and TGF-β, respectively. After 24h, supernatant of cells were investigated for 
changes in HBsAg secretion, as an indicator of HBV replication. There were no 
significant changes detectable in secreted HBV antigens (Figure 26). This indicates that 
SB203580 has no negative impact on HBV replication. 
 
 
Figure 4.26: SB203580 has no impact on HBV 
replication. HepG2.2.15 cells were starved 
overnight and treated with SB203580 (5µM) for 
2hrs prior to TGF-β treatment (5ng/ml) for 24hrs. 
In summary, HepG2.2.15 cells, able to replicate HBV in contrast to their parental strain 
HepG2, exhibit reduced Smad3 phosphorylation and transcriptional activity. Elevated 
Akt activation interfered with TGF-β induced apoptosis, which could be rescued by Akt 
inhibition. The results suggest that TGF-β induced apoptosis is probably not mediated 
by canonical Smad3 signaling, as investigated by Smad7 overexpression and Smad3 
downregulation. Usage of p38 inhibitor SB203580 was able to reduce TGF-β induced 
apoptosis upon Akt inhibition. However, lentiviral knockdown of p38 revealed, that p38 
might not mediate TGF-β induced apoptosis. A negative effect on HBV replication due to 
SB203580 was excluded indicating that the effect on TGF-β induced apoptosis of 
SB203580 might be upstream of p38. 
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To summarize this chapter, microarray results suggest that HBV is able to interfere with 
TGF-β signaling pathway, indicated by abrogation of TGF-β target gene expression and 
reduction of Smad3 phosphorylation levels. HBV infection inhibited TGF-β signaling, but 
activated the p53 and the mTOR signaling pathways. Further, TGF-β dependent p21 
expression was inhibited by HBV infection, indicating inhibition of TGF-β induced 
apoptosis. In HepG2.2.15 cells, HBV was able to increase Akt activation, thereby 
probably interfering with TGF-β dependent apoptosis. Increase of Akt activation was 
reported to be associated with HBV infection before [192] [193]. Further, Conery et al 
reported that Akt interacts with unphosphorylated Smad3 in the cytoplasm, preventing 
its phosphorylation and translocation to the nucleus, and thereby inhibiting TGF-β 
induced apoptosis [54]. Functional analysis of this interaction in this study could not 
finally explain the mechanistic background. However, it seems obvious, that complex 
crosstalk of TGF-β mediated apoptotic signals with survival signaling pathways are 
altered in HBV infected cells inducing survival signaling pathways and inhibiting TGF-β 
tumor suppressive effects. 
 
4.2 Impact of HCV on TGF-β signaling in human hepatocytes 
TGF-β signaling controls tissue homeostasis by cytostatic effects, e.g. apoptosis and 
proliferation inhibition. In HCV infected patients, TGF-β levels are upregulated [197-199] 
and in progressed disease stages, it can facilitate development of liver cancer and 
metastasis. Investigating the impact of HCV infection on TGF-β signaling can lead to 
efficient HCC treatment in HCV infected patients. However, research using complete 
and infectious HCV virus is often limited due to safety issues. Elucidating the impact of 
HCV on TGF-β signaling in more detail can be approached by studying effects of single 
HCV proteins. One of the most prominent HCV proteins, HCV core protein, is known to 
have an impact on cell growth, apoptosis and carcinogenesis [125]. In this study the 
interaction between TGF-β signaling and HCV core protein, and full HCV virus, 
respectively, was investigated. 
 
4.2.1 HCV core protein impairs TGF-β induced apoptosis in Huh7 cells 
As Huh7 cells are sensitive for an apoptotic response upon TGF-β [200], Huh7 cells 
stably expressing HCV core protein were generated. Cells were transfected with the 
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plasmid coding for the HCV core protein and selected by Neomycin (400µg/ml) for 21 
days until single cell clones had developed. To assure proper expression of HCV core 
protein, primers flanking the sequence of HCV core protein were used. Control cells, 
which were stably transfected with empty vector, served as a negative control for 
subsequent PCR against HCV core protein, as well as control cell line for following 
experiments (Figure 4.27). Due to these specific mutations, immunoblot detection of 
overexpressed HCV core protein by a commercially available antibody was not possible 
in this study. Instead, proper HCV core protein expression was initially proven by PCR. 
 
Figure 4.27: Generation of Huh7-HCV core cells. 
Huh7 cells were transfected for 6h with 4µg plasmid, 
encoding HCV core protein, using Lipofectamine 
2000. Afterwards, cells were placed on starvation 
medium for 48h prior to selection of successful 
transfected cells by Neomycin (400µg/ml). Medium was changed every 2-3 days. Selection took place for 
21 days until single cell clones had developed. Expression of HCV core protein was proven by PCR using 
designed primers flanking the sequence of HCV core protein. 
 
 
4.2.1.1 HCV core protein interferes with canonical TGF-β signaling 
Cheng et al reported that HCV core protein interacts with Smad3 and inhibits its 
transcriptional activity [120]. To assess interference of HCV core protein with canonical 
TGF-β signaling in Huh7-HCV core cells, phosphorylation levels and transcriptional 
activity of Smad3 were investigated. Huh7-HCV core cells and Huh7-empty vector cells 
were treated with TGF-β for 1 and 24hrs. HCV core protein reduced Smad3 
phosphorylation levels from prolonged to transient compared to Huh7-empty vector cells 
(Figure 4.28). Smad3 expression levels were equal in both cell lines. No differences 
were seen at Smad2 phosphorylation levels at 24hrs TGF-β. 
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Figure 4.28: HCV core protein reduced 
Smad3 phosphorylation levels. Cells were 
starved overnight prior to treatment with TGF-β 
(5ng/ml) for the indicated time points. Protein 
lysates were subjected to immunoblot analysis 
of pSmad3, Smad3, Smad2, and pSmad2. 
Tubulin served as loading control. 
 
CAGA reporter assay was performed to investigate the impact of impaired Smad3 
phosphorylation on its transcriptional activity. A reduced Smad3 transcriptional activity 
was detected upon TGF-β treatment in Huh7-HCV core cells compared to Huh7-empty 
vector cells (Figure 4.29) after 6 and 12hrs. This confirmed the results already reported 
before [120]. 
 
 
Figure 4.29: Smad3 transcriptional activity is 
reduced in Huh7-HCV core cells. Cells were 
cotransfected with plasmid encoding β-Gal and 
the CAGA sequence, respectively, using 
Lipofectamine 2000 for 4hrs. Cells were starved 
overnight prior to treatment with TGF-β (5ng/ml) 
for the indicated time points. **p<0.02. 
 
Smad7 is a target gene of TGF-β. To investigate the downstream impact of impaired 
Smad3 phosphorylation and activity on the induction of Smad7 promoter, Huh7-HCV 
core cells and Huh7-empty vector cells were transfected with plasmid encoding Smad7 
promoter. As investigated by qPCR, endogenous Smad7 expression levels were equal 
in both cell lines (Figure 4.30 A). As expected from downregulated Smad3 activation, 
reduced Smad7 promoter activity was demonstrated in Huh7-HCV core cells. Upon 
TGF-β treatment (Figure 4.30 B). This suggests that the interference of HCV core 
protein and Smad3 indeed have downstream impact on TGF-β induced gene 
expression. 
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Figure 4.30: HCV core protein reduced Smad7 Promoter Activity. (A) Basal Smad7 expression was 
investigated by qPCR in Huh7-empty vector and Huh7-HCV core cells after 48h starvation. (B) Smad7 
promoter activity assay. Cells were cotransfected with plasmid encoding β-Gal and Smad7 promoter 
sequence, respectively, using Lipofectamine 2000 for 4hrs. Cells were starved overnight, prior to 
treatment with 5ng/ml TGF-β for the indicated time points. **p<0.02 
 
4.2.1.2 HCV core protein reduced TGF-β induced apoptosis 
It was reported before that HCV core protein and Smad3 interact with each other, which 
results in reduced TGF-β induced apoptosis [120]. To verify reduced TGF-β induced 
apoptosis in Huh7-HCV core cells, generated in this study, a LDH assay was performed 
after 48 and 72hrs TGF-β treatment. In Huh7-HCV core cells LDH release was reduced 
compared to Huh7-empty vector cells (Figure 4.31). After 72hrs TGF-β treatment, this 
effect was even more prominent and the number of dead cells increased up to 50%.  
 
 
Figure 4.31: HCV core protein reduced TGF-β 
induced apoptosis. Cells were starved 
overnight prior to treatment with TGF-β (5ng/ml) 
for the indicated time points. LDH release was 
measured in the supernatant. **p<0.02 
 
Reduced TGF-β dependent signaling was also confirmed by investigation of TGF-β 
target genes responsible for cell cycle arrest. In Huh7-HCV core cells, cell cycle arrest 
protein p21, as well as p15, were not elevated upon TGF-β for 24hrs as found in Huh7-
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empty vector cells (Figure 4.32). Further, the growth arrest and DNA-damage-inducible 
gene β, GADD45β, was not induced in Huh7-HCV core cells upon TGF-β treatment. 
These results suggest that interference of HCV core protein with TGF-β signaling results 
in a reduced apoptotic response upon TGF-β treatment. 
 
 
 
 
 
 
Figure 4.32: HCV core protein abolishes expression of TGF-β dependent cell cycle proteins p21 
and p15, as well as of GADD45β. Cells were starved overnight prior to treatment with TGF-β (5ng/ml) for 
the indicated time points. (A) Protein lysates were subjected to immunoblot analysis of p21. Tubulin 
served as loading control. (B, C, D) cDNA was subjected to semi-quantitative PCR of p15 and GADD45β. 
β2MG served as housekeeping gene. Quantitative evaluation of (C) p15 and (D) GADD45β. **p<0.02 
 
4.2.1.3 HCV core protein induces proliferation and migration TGF-β 
independently 
Proliferation and migration are hallmarks of EMT. It was reported before, that HCV core 
protein induces proliferation [114] and migration [201] [202]. The impact of TGF-β in the 
course of HCC can shift from tumor suppressor towards tumor promoter and facilitate 
proliferation and migration [203] [204]. To investigate whether HCV core protein and 
A B 
C D 
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TGF-β induce these typical characteristics of EMT, MTT and transwell assays were 
performed. 
As HCV core protein is also reported to induce TGF-β expression [109], basal TGF-β 
expression levels in both cell lines were measured by qPCR. However, TGF-β 
expression levels were equal (Figure 4.33 A) excluding enhanced autocrine TGF-β 
signaling in Huh7-HCV core cells. 
Expression of HCV core protein increased basal proliferation about 2-fold (Figure 4.33 
B). Treatment with TGF-β had no further impact on proliferation in Huh7-HCV core cells. 
TGF-β independency of proliferation was shown by usage of TGF-β type I receptor 
inhibitor SB431542 which did not reduce proliferation of Huh7-HCV core cells and Huh7-
empty vector cells. 
 
 
Figure 4.33: Increased proliferation of Huh7-HCV core cells is TGF-β independent. (A) Basal TGF-β 
expression was investigated by qPCR in Huh7-empty vector and Huh7-HCV core cells after 48h 
starvation. (B) Cells were starved overnight prior to treatment with TGF-β for 48hrs or type I TGF-β 
receptor inhibitor SB431542 (SB43). MTT was added to the cells for 4hrs until measurement. ns = not 
significant. **p<0.02 
 
To assess the impact of HCV core protein and TGF-β in regard to migration, a transwell 
assay was performed. The basal migration rate of Huh7-HCV core cells was increased 
around 40% compared to Huh7-empty vector cells (Figure 4.34). However, cell 
migration in both cell types was not significantly increased upon TGF-β treatment. 
A B 
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Figure 4.34: Migration is induced in 
Huh7-HCV core cells. Migration was 
investigated by transwell assay, comparing 
TGF-β treated (5ng/ml) to PBS (control) 
treated cells after 24hrs. ns = not 
significant. **p<0.02 
 
Although TGF-β has been reported to be involved in the transition of an epithelial cell 
into a mesenchymal cell during cancer progression [17], induced proliferation and 
migration were TGF-β independent in Huh7-HCV-core cells. However, the results 
described here suggest that HCV core protein may induce EMT in Huh7-HCV core cells 
and direct impact of TGF-β on this cancer related mechanism needs to be investigated. 
 
4.2.1.4 HCV core protein induces Vimentin expression independent of  
TGF-β 
EMT changes a cells morphology and phenotype; cells lose their typical epithelial 
phenotype and adopt a spindle-shaped phenotype [205]. To investigate EMT in Huh7-
HCV core cells, the morphology was regarded and the expression of typical EMT 
markers was measured.  
Expression of HCV core protein altered the morphology of Huh7-HCV core cells 
compared to Huh7-empty vector cells (Figure 4.35 A). Huh7-HCV core cells had a more 
rounded morphology and a smoother cell surface compared to Huh7-empty vector cells.  
ZO-I delocalization, increased Vimentin expression and stress fiber formation are 
hallmarks of EMT. To elucidate, whether Huh7-HCV core cells are more prone to TGF-β 
induced EMT, cells were investigated by immunofluorescence for markers of EMT. After 
48h TGF-β treatment, Huh7-HCV core cells displayed no delocalization of ZO-I 
compared to Huh7-empty vector cells (Figure 4.35 B). The same result holds true for 
stress fiber formation; only Huh7-empty vector cells had stress fiber formation and ZO-I 
delocalization after 48hrs TGF-β treatment. However, this effect can also be assigned to 
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TGF-β induced apoptosis, as apoptosis facilitates stress fiber formation and membrane 
degradation. EMT is considered to be without signs of apoptosis. Expression of 
Vimentin, a marker of mesenchymal cells, was not changed upon TGF-β treatment, 
neither in Huh7-empty vector or Huh7-HCV core cells. However, basal Vimentin 
expression was higher in Huh7-HCV core cells as in Huh7-empty vector cells. These 
results suggest that HCV core protein induces EMT in Huh7 cells indicated by a higher 
basal Vimentin expression. 
 
 
 
 
Figure 4.35: HCV core protein induces Vimentin expression. (A) Morphology of cells examined by light 
microscopy (B) Cells were grown on cover slips and treated with TGF-β or not for 48hrs. For fixation, cells 
were incubated with 4% PFA (20min) until incubation with indicated antibodies or Phalloidin, respectively. 
A 
B 
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4.2.1.5 Impact of HCV core protein on other cell signaling pathways and 
apoptosis related proteins 
TGF-β induced apoptosis and Smad signaling is inhibited by HCV core protein in this 
study. HCV core protein might induce EMT in Huh7 cells, as migration and proliferation, 
as well as Vimentin expression, were elevated. Hence, it was of major interest to 
investigate the effect of HCV core protein on other cell signaling pathways, which might 
lead to increased cell proliferation, migration and survival. Immunoblot analysis showed 
that protein levels of anti-apoptotic Bcl-2 were higher in Huh7-HCV core cells compared 
to Huh7-empty vector cells (Figure 4.36 A). The increased levels of Bcl-2 can counteract 
TGF-β induced apoptosis. No changes were observed in Erk or p38 phosphorylation 
levels, which play a role in cell proliferation and apoptosis, respectively. Akt signaling 
plays a role in cell survival by antagonizing apoptotic pathways, like e.g. TGF-β 
signaling. Huh7-HCV core cells had higher Akt phosphorylation which decreased upon 
TGF-β treatment. This might indicate that Akt signaling plays no significant role in the 
inhibition of TGF-β induced apoptosis, and apoptosis has to be inhibited by other 
mechanisms. E-Cadherin expression, a marker of epithelial cells, was equal in Huh7-
HCV core and Huh7-empty vector cells. Interestingly, CTGF a fibrotic cytokine, involved 
in growth and migration [206] [207] [208], was highly increased in HCV core expressing 
cells. Although CTGF is a target gene of TGF-β signaling, it was not further increased 
upon TGF-β treatment (Figure 4.36 B). This suggests that HCV core protein induced 
CTGF expression is one driver of HCV dependent fibrosis. 
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Figure 4.36: HCV core protein induces CTGF expression. Cells were starved overnight prior to 
treatment with TGF-β (5ng/ml). Protein lysates were subjected to immunoblot analysis of pSmad3, 
pSmad2, Bcl-2, p21, PCNA, pAkt, p-p38, pErk, E-Cadherin, CTGF levels. Tubulin served as loading 
control. (A) Impact of HCV core protein on cell signaling pathways. (B) Elevated CTGF expression in 
Huh7-HCV core cells. 
 
Taken together, results obtained show that HCV core protein interferes with TGF-β 
tumor-suppressor effects, indicated by the abrogation of TGF-β induced apoptosis and 
Smad3 signaling. However, investigations further suggest, that the effects of TGF-β are 
not shifted towards tumor promotion by HCV core protein; rather HCV core protein 
induces cell proliferation and migration independent of TGF-β. Which pathways or 
A 
B 
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cellular changes are responsible for induced migration and proliferation has to be 
clarified in detail. Subsequently, the observation that HCV core protein induced CTGF 
expression was of great interest. CTGF is known to play a major role in liver fibrosis and 
elucidation of the cellular mechanism responsible for CTGF expression could have 
therapeutic value in HCV infection. 
 
4.2.2 Influence of HCV on TGF-β signaling 
Overexpression of HCV core protein impaired TGF-β induced apoptosis and reduced 
Smad3 phosphorylation and transcriptional activity. In order to confirm these results, 
Huh7.5 cells sensitive for full HCV replication were used. Due to safety reasons, most 
assays performed in HCV-core cells were not possible to perform with HCV infected 
Huh7.5 cells. Assays, possible to perform were limited to Immunoblot analysis and 
luciferase reporter assay. 
 
4.2.2.1 TGF-β has no influence on HCV replication 
To assess influence of TGF-β on HCV replication, Huh7.5 cells were electroporated with 
HCV RNA and treated with TGF-β for 1 or 24hrs, respectively. Huh7.5 cells 
electroporated with water served as control cells (uninfected). Attached to the HCV RNA 
is a Renilla luciferase reporter, which allows for the verification of HCV replication in 
Huh7.5 cells (see 3.1.8). Luciferase reporter activity revealed equal levels of replication 
within the different experiments. Further, HCV replication was not influenced by TGF-β 
treatment (Figure 4.37). 
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Figure 4.37: HCV replication levels were equal 
within the different experiments and 
independent of TGF-β treatment. Cells were 
electroporated with in vitro transcribed HCV 
RNA. The next day, cells were treated with TGF-
β for the indicated time points and harvested to 
determine viral replication by Luciferase Assay. 
 
4.2.2.2 Interference of HCV and Smad signaling 
To assess interference of HCV replication in Huh7.5 cells with canonical TGF-β 
signaling, phosphorylation levels of Smad3 were investigated. Therefore, Huh7.5 cells, 
electroporated with HCV RNA, were treated with TGF-β for 1 or 24hrs, respectively. 
Huh7.5 cells electroporated with water served as control cells (uninfected). The 
experiment was performed four times (#1-4), however, Smad3 phosphorylation was not 
reduced in Huh7.5 cells replicating HCV as found in HCV-core cells (Figure 4.38 A and 
B). CAGA reporter assay revealed no differences in Smad3 transcriptional activity 
between control cells and HCV replicating cells (Figure 4.38 C). 
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Figure 4.38: Full HCV infection has no impact on Smad3 phosphorylation. Cells were electroporated 
with in vitro transcribed HCV RNA or water. (A, B) The next day, cells were treated with TGF-β for the 
indicated time points. Protein lysates of four independent experiments (#1, 2, 3, 4) were subjected to 
immunoblot analysis of pSmad3. Tubulin served as loading control. (B) Quantitative evaluation of 
pSmad3. (C) To assess Smad3 transcriptional activity, cells were cotransfected with plasmid encoding β-
Gal and the CAGA sequence, respectively, using Lipofectamine 2000 for 4hrs. Cells were starved 
overnight prior to treatment with TGF-β (5ng/ml) for the indicated time points. 
A 
C 
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5 DISCUSSION 
TGF-β plays a pivotal role in liver cell signaling. In healthy tissue and early stages of 
liver disease, TGF-β signaling controls tissue homeostasis by promoting cytostatic 
effects, e.g. apoptosis and proliferation inhibition towards injured and regenerating 
hepatocytes, and wound closure via activating fibroblasts and stellate cells in injured 
liver [10] [82]. Chronic HBV and HCV infection have been clearly recognized as an 
etiological and significant risk factor for HCC development. HBV and HCV induce 
deregulation of cellular signaling on which the subsequent development of liver 
inflammation further promotes tumor development [209]. Elucidating the role of HBV/ 
HCV – TGF-β crosstalk may be beneficial for the development of successful medication. 
The aim of this study was to investigate the impact of viral infection on TGF-β-
dependent signaling pathway, its outcome and progression to HCC. The group of Prof. 
Dooley has previously shown that in some HCC cell lines with transcriptional Smad3 
activity TGF-β induces apoptosis and inhibits cell proliferation. In contrast, TGF-β-
dependent cytostatic effects are inhibited in other HCC cell lines which have low Smad3 
transcriptional activity. The results obtained in this study hypothesize that HBV and HCV 
counteract TGF-β tumor suppressive effects by reducing Smad3 activity, thereby 
facilitating the escape of virus-infected hepatocytes from TGF-β-induced apoptosis. 
 
5.1 Impact of HBV on TGF-β signaling in human hepatocytes 
5.1.1 HBV infection impairs TGF-β signaling in primary human 
hepatocytes 
As TGF-β is an important liver cytokine, this study investigated the impact of HBV 
infection on TGF-β signaling. To elucidate the effects of HBV on host gene expression in 
the absence of e.g. pathogenic reactions of the immune system and other cell types, 
isolated PHHs as experimental model were chosen. This also exhibits an advantage 
compared to former studies using cell lines as model system, as cell lines are 
transformed cells which have many physiological properties that are altered in the 
original state of hepatocytes [210]. Although the cultivation of PHHs is more complex 
and expensive, PHHs are easier to infect with HBV as cell lines. However, if PHHs were 
used in the past, infection efficiency with HBV was only up to 50% [183]. In the study 
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presented here HBV infection efficiency of PHHs of nearly 100% was reached, thus 
representing a valuable model for the investigation of HBV infection and replication 
impact on the PHH transcriptome. 
PHHs from three independent donors were infected with HBV and cultivated for 7 days 
until treatment with TGF-β for 1 and 24hrs, respectively. It has been reported that HBV 
has evolved mechanisms to maintain its replication rate at a low level that does not 
compromise the normal functions of hepatocytes; this allows the host cell to remain 
healthy. The low replication rate is achieved through the regulation of the level of HBV 
cccDNA that accumulates in the nucleus [211]. In regard to this, array analysis was 
performed at the highest peak of viral replication 8 days post infection, as determined in 
pre-experiments upon measurement of HBsAg and HBeAg levels in the supernatant. 
RNA was isolated and cRNA was hybridized to Affymetrix Human Genome 1.0 ST Array 
with subsequent analysis of genomic data by encapsulated R application. To elucidate 
common and solid influences of HBV infection, gene alterations which were identical in 
all three donors were taken into account for further studies; donor-specific regulations 
were disregarded. 
Comparison and comprehensive investigation of the alterations in the gene expression 
profile of PHHs infected with HBV or not revealed that only 12 genes were regulated 
upon HBV infection. The most upregulated gene was TYMS, actually involved in DNA 
synthesis and repair. It is induced by the transcription factor LSF/TFCP2. LSF and 
TYMS have recently been associated to liver cancer proliferation and progression. LSF 
was found to be overexpressed in HCC cell lines and HCC patients. Stages and grades 
of the disease correlated with LSF expression levels. Hep3B cells stably overexpressing 
LSF displayed a significant increase in proliferation, colony formation and Matrigel 
invasion [155] [156]. The oncogene MDM2, which plays a role in p53 signaling pathway 
[212] [146], was upregulated as well. p53 signaling pathway is involved in apoptosis and 
DNA repair, and deregulated p53 signaling can lead to impaired apoptosis and 
increased proliferation. MDM2 binds to p53 and leads to its degradation. An increase in 
MDM2 results in the direct inhibition of p53 transcriptional activity, enabling the 
damaged cells to escape the cell-cycle checkpoint control and to become tumorigenic. 
MDM2 was shown to be upregulated in several human tumors and reported to be 
involved in tumor formation. In vitro studies showed, that in Huh7 cells, replicating HBV, 
deregulation of cell cycle and cell viability was due to increased upregulation of MDM2 
[213]. The protein DDB2 was also upregulated upon HBV infection. In contrary, DDB2 
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was reported to counteract HBx stabilization upon protein interaction [214]. SPATA18 
was upregulated, which is known to regulate the quality of mitochondria by repairing or 
degrading damaged mitochondria. Recently, SPATA18 was reported to be a 
transcriptional target of p53 and p63. Due to their homology, p63 can compensate for a 
loss of p53 activity. As in this study p53 activity may be inhibited, upregulation of 
SPATA18 and maintenance of p53 signaling could be triggered by p63. These results 
suggest that upon upregulation of DDB2 and SPATA18 the cell tries to minimize the 
damage of HBV by counteracting HBx stabilization, and to maintain mitochondria quality 
and p53 signaling. 
KEGG Pathway analysis revealed that the p53 signaling pathway was regulated upon 
HBV infection. Its deregulation was associated to several types of cancer, like glioma, 
chronic myeloid leukemia, bladder cancer, melanoma, and prostate cancer before. This 
shows that HBV infection caused carcinogenesis-related changes in host cell gene 
expression, with p53 signaling pathway as the most prominent one. A similar experiment 
has been done by Ryu et al. 2006, although PHH infection efficiency was around 50% 
only in their study. They infected PHHs of 3 independent donors for 8 days [183] and 
identified 45 downregulated genes, most of them were transcription factors related to 
RNA polymerase II; around 53 genes were upregulated, including many growth and 
tumor-related genes, positive genes for tumor growth and proliferation, like GDF11 and 
NOL1; Hence, gene regulation of uninfected PHHs can cover the impact of HBV. 
Another study by Iizuka et al. 2002 investigated liver biopsies of HBV-associated HCC. 
They found 31 upregulated genes, including imprinted genes (H19 and IGF2) and genes 
related to signal transduction, transcription and metastasis (MAP2K4, MAP2K5, SFI, 
SIAHBPI, MYOG, MMP9, VEGF) [215]. Another study by Nakanishi et al. 2005 using 
Huh6 cells transfected with HBV plasmid identified only 14 regulated genes; CD44, high 
mobility group protein-1, thymosin beta-10, 27kD heat shock protein were upregulated 
and NM23-H1, caspase-3, BAX were downregulated [216]. In line with our study, much 
evidence accumulates showing that HBV is well adapted to noncytopathic replication in 
hepatocytes inducing only minor alteration in gene expression and little or no damage to 
the cell [143] [65]. It is reported, that HBV has rather the preference to replicate in 
quiescent cells, since virus replication can be maintained in hepatocytes without signs of 
apoptosis during prolonged chronic infection [217]. Generally, liver disease is probably 
produced and induced through immune mediated mechanism aiming on downregulation 
of virus replication and elimination of infected hepatocytes [144] [145]. 
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Furthermore, no uniform signature of HBV-induced gene alterations could be identified 
yet. This highlights that HBV infection may cause different outcomes depending on the 
diverse genetic and epigenetic background of each patient. As identified in the Heat 
Map analysis, basal gene expression of each donor was quite different. HBV infection 
had only a minor impact on gene regulation but led to individual alterations in each 
donor, with only a few common ones. TGF-β treatment had the most impact on gene 
expression in each donor, but was unexpectedly less influenced by HBV infection. 
Interestingly, HBV infection decreased the number of TGF-β regulated target genes; this 
can be due to the impairment of TGF-β signaling pathway by HBV.  
Comparison of the gene expression profiles of HBV infected to uninfected PHHs treated 
with TGF-β identified an upregulation of typical early TGF-β target genes, like Smad7, 
Serpine1 (PAI-1), p21, or ID1 in uninfected PHHs only [218]. Significant regulated 
pathways were identified by KEGG pathway analysis. This revealed that TGF-β 
treatment of uninfected PHHs, but not of HBV infected PHHs, resulted in regulation of 
TGF-β signaling pathway. In HBV infected PHHs regulation of TGF-β signaling pathway 
was inhibited. Immunoblot analysis of HBV infected PHHs revealed reduced Smad3 
phosphorylation upon 48hrs TGF-β treatment. Investigations of mechanistical details 
made in HBV replicating HepG2.2.15 cells support the hypothesis of impaired TGF-β 
signaling and reduced Smad3 phosphorylation levels upon TGF-β treatment. 
Furthermore, Akt signaling was found to be activated in HepG2.2.15 cells.  mTOR, which 
was found to be regulated in the microarray analysis of HBV infected PHHs, is a 
downstream target of Akt survival pathway. These results support current knowledge, 
showing that viruses induce activation of cell survival pathways to inhibit death of cells 
they infect [89] [188] [189] [190] [191]. 
In summary, the data are consistent with the hypothesis that HBV infection is 
noncytopathic, and that carcinogenesis-related transformations are mainly mediated by 
the impact of the immune system on the infected cell. Results reported before showed 
that there is no uniform set of genes regulated within the HBV DNA profile during the 
initial host response to HBV infection [219]. Several reasons account for this. First, 
obtained microarray results can be different depending on the bioinformatic tools used 
for analysis of genomic data. Second, usage of different microarrays and different 
experimental protocols hamper the comparison of genomic analysis of HBV infection 
among each other. Third, diversity of donor PHHs, due to for example age, gender, race 
and nutritional status, could result in an unwanted bias. Generalizing gene expression 
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patterns to establish an overall applicable treatment option upon microarray analysis for 
HBV-infected patients is apparently impossible. However thorough mechanistical studies 
of positive hits improve our understanding of TGF-β signaling in HBV infected patients 
and thus might help to provide personalized therapeutical possibilities in the future. As 
this study examined a relatively small number of donors, further validation in a larger set 
of donors will be required. Nevertheless, these results suggest that HBV infection 
induces the host cell to adopt a malignant phenotype upon TGF-β treatment through 
alterations in the expression levels of a set of carcinogenesis-related genes and the 
inhibition of TGF-β signaling pathway regulation. However, the biologic significance of 
some of the HBV mediated alterations in TGF-β treated hepatocytes still remain unclear. 
These findings may serve as a first step towards the comprehensive understanding of 
TGF-β effects on HBV infected hepatocytes and its relation to the development or 
progression of HCC; And determination of differentially expressed genes may have 
diagnostic and prognostic value for HBV infected patients with HCC. 
 
5.1.2 Akt deactivation sensitizes HepG2.2.15 cells for TGF-β induced 
apoptosis 
Microarray analysis revealed an impaired TGF-β signaling pathway in HBV infected 
PHHs upon treatment with TGF-β. Due to the limited availability of PHHs, microarray 
results were confirmed in HepG2.2.15 cells, replicating HBV. HepG2.2.15 cells showed 
that TGF-β dependent Smad3 transcriptional activity was reduced and Smad3 
phosphorylation levels were transient compared to their parental HepG2 cells. Both, 
HepG2.2.15 and HepG2 cells were insensitive towards TGF-β induced apoptosis. 
However, there had to be different regulation mechanisms responsible for apoptosis 
resistance maybe via additional impact of HBV in HepG2.2.15 cells. One explanation for 
the cytostatic insensitivity of HepG2.2.15 could be that HBV impair Smad3 activity which 
ultimately leads to the abrogation of canonical TGF-β signaling responsible for 
apoptosis. The impaired TGF-β induced apoptosis is further supported by a significant 
upregulation of Akt signaling pathway in HepG2.2.15 cells. This is in line with the 
observation of an upregulated mTOR signaling pathway in HBV infected PHHs, which is 
a downstream target of Akt signaling [220]. Generally Akt signaling plays a role in cell 
survival by antagonizing apoptotic pathways, like e.g. TGF-β signaling. An increase in 
Akt activation has been reported to be associated with viral infection [192] [193]. Viral 
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replication is reported to induce cell stress which leads to an increase in cell apoptosis. 
To prevent apoptosis of cells they infect, HBV and other viruses upregulate PI3K/Akt 
signaling pathway, which ultimately may contribute to uncontrolled proliferation of host 
cells [188] [89] [189] [190]. Shih et al. 2000 reported further, that HBx overexpression in 
Hep3B cells inhibits TGF-β induced apoptosis through activation of PI3K pathway; 
however, they did not elucidate the exact mechanism of TGF-β induced apoptosis [89]. 
Thus, I asked whether upregulation of Akt signaling found in this study may directly 
counteract TGF-β induced apoptosis.  Akt deactivation by its specific inhibitor LY294002 
sensitized HepG2.2.15 cells for TGF-β induced apoptosis. Further investigations 
revealed that induction of apoptosis by TGF-β occurred most likely Smad3 independent, 
as Smad3 activity was decreased in HepG2.2.15 cells; And inhibition of canonical Smad 
signaling by overexpression of Smad7, as well as partial knockdown of Smad3, did not 
decrease TGF-β induced apoptosis upon Akt inhibition. Vice versa, overexpression of 
Smad3 did not further increase TGF-β induced apoptosis upon Akt inhibition. 
It is well accepted that TGF-β is able to exert its effect also via non-canonical signaling 
pathways. SB203580, a selective inhibitor of p38 MAPK signaling, inhibits the activation 
of MAPKAPK-2 by p38MAPK and subsequent phosphorylation of HSP27 [221]. Upon 
usage of SB203580, TGF-β induced apoptosis upon Akt deactivation could be 
decreased. This suggests in line with previous reports, that TGF-β can mediate its 
apoptotic effect via the p38 pathway [51] [52]. However, I could not prove p38 
phosphorylation by immunoblot analysis. Since there was no basal p38 phosphorylation 
detectable it was of further interest to investigate whether reduction of TGF-β induced 
apoptosis upon Akt deactivation is dependent on p38 MAPK or whether it is impaired 
due to some unspecific effect of the inhibitor SB203580. Therefore, p38 was 
downregulated in HepG2.2.15 cells by lentivirus carrying siRNA against p38 MAPK. A 
complete downregulation of p38 was not achieved and this approach did not reduce 
TGF-β induced apoptosis upon Akt deactivation as compared to usage of SB203580. 
Thus a satisfying interpretation of the data is not yet possible. So far the data basically 
suggests that p38 MAPK is not involved in TGF-β induced apoptosis and the effect of 
SB203580 has to be either upstream of p38 MAPK or is due to another unspecific effect. 
Unspecificity of SB203580 has already been reported before several times, e.g. 
SB203580 is able to inhibit Akt phosphorylation and retinoblastoma 
hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 [222]; 
SB203580 is able to inhibit cyclooxygenase-1 and -2 non-specifically [223], and it 
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enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon 
ERK pathway [224].  
One other unspecific mechanism how SB203580 can exert its TGF-β desensitizing 
function could be a negative impact on HBV replication, which in turn leads to less cell 
stress making the cells more resistant towards TGF-β induced apoptosis. Accordingly, 
Chang et al. published in 2008 that suppression of phosphorylation of p38 by inhibitor 
SB203580 could inhibit intracellular HBV replication in Huh7 cells transiently transfected 
with HBV plasmid [225]. However, measurement of HBsAg levels in HepG2.2.15 could 
not confirm any effect on HBV replication upon treatment with SB203580. High basal 
p38 phosphorylation levels in Huh7 cells could play a role for this different observation.  
In future experiments, one approach to elucidate the influence of HBV replication on 
TGF-β induced apoptosis upon Akt inhibition could be the usage of HBV-specific 3p-
siRNAs, which is able to target HBV RNAs to inhibit HBV replication [226]. Then, HBV 
could be easily switched “on” and “off” within the same cell model with the same genetic 
and cellular background. 
 
In summary, the study presented contributes to knowledge about the impact of HBV 
infection on TGF-β signaling. The obtained results show that the tumor-suppressive 
effect of TGF-β signaling is abrogated due to upregulation of survival pathways by HBV. 
HBV induced activation of Akt survival signaling pathway to counteract the cytostatic 
effects of TGF-β, which could be rescued by inhibition of Akt activation by its inhibitor 
LY294002. However, mechanistical background of TGF-β induced apoptosis upon Akt 
deactivation, influence of SB203580 and possible impact of HBV replication could not be 
solved in this study and remains to be elucidated. 
In the future, it is important to understand the molecular mechanism leading to the 
abrogation of TGF-β induced apoptosis and the upregulation of survival pathways by 
HBV in order to develop treatment strategies interrupting the responsible pathways to 
prevent viral carcinogenesis.  
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5.2 Impact of HCV infection on TGF-β signaling in human 
hepatocytes 
5.2.1 Impact of HCV core protein on TGF-β signaling in Huh7 cells 
 
Huh7 cells represent an ideal model system to investigate the impact of HCV core 
protein on TGF-β signaling as they are sensitive for cytostatic TGF-β effects and 
canonical Smad3 dependent signaling is inducible by TGF-β treatment. Huh7 cells were 
stably transfected with plasmid encoding HCV core protein (kind gift of S. Battaglia, 
France). This HCV core protein is a natural variant which was isolated from a liver tumor 
and exhibits a limited number of non-synonymous mutations when compared to a core 
reference sequence of the same genotype (C1b) [124]. Further, the substitutions found 
in the HCV core variant were unique to the tumor tissue and not to HCV core protein as 
found in non-tumor tissue. The tumor sequence did not exhibit any hot-spot mutations, 
but displayed amino-acid substitutions in the central (aa 59–126) and C-terminal (aa 
127–191) domains. Overall, this highlights that even though core is a structural protein 
and highly conserved within the different genotypes, quasispecies develop during the 
course of chronic infection due to the high error rate of the RNA-Polymerase. These 
non-synonymous mutations can be specific to tumor tissue [94]. 
Several groups reported the influence of HCV core protein expression on TGF-β 
dependent cell cycle control, resulting in a downregulation of cyclin-dependent kinase 
inhibitor p21 in HepG2 and in murine fibroblast NIH 3T3 cells, respectively. Mechanistic 
background of this inhibitory effect was elucidated later, showing decreased DNA 
binding abilities of Smad3 due to an interaction with HCV core protein [116] [117]. HCV 
core protein may directly interact with the MH1 domain of Smad3; thereby blocking TGF-
β/Smad3 mediated transcriptional activation through interference with the DNA binding 
ability of Smad3, but not with its nuclear translocation ability. This interaction leads to 
repression of TGF-β/Smad3 mediated apoptosis as investigated by TGF-β induced p21 
promoter activation. 
In this study, a reduced Smad3 phosphorylation and transcriptional activity, concomitant 
with an inhibition of TGF-β induced apoptosis was confirmed in Huh7-HCV core cells. 
Aim of this study was then to investigate whether and how HCV core protein shifts TGF-
β signaling from tumor suppressor towards tumor promoter. As TGF-β can induce 
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proliferation and migration during disease progression [203] [204], the impact of HCV 
core protein was analyzed using MTT and transwell assays. Huh7-HCV core cells 
showed increased proliferation and migration rates, however independent of TGF-β, 
which might be associated with EMT. Indeed Huh7-HCV core cells exhibited a change in 
shape and morphology compared to Huh7-empty vector cells. ZO-I delocalization and 
stress fiber formation are hallmarks of EMT and can be induced upon TGF-β [15] [227]. 
Huh7-empty vector cells displayed ZO-I delocalization and stress fiber formation upon 
TGF-β. Apoptosis induces cell stress and membrane degradation, which leads to ZO-I 
delocalization and stress fiber formation. However, Huh7-empty vector cells are 
sensitive for TGF-β induced apoptosis and EMT is regarded to be without signs of 
apoptosis. Another hallmark of EMT is Vimentin expression. Huh7-HCV core cells had 
higher levels of Vimentin expression as Huh7-empty vector cells, which were however, 
TGF-β independent. It was reported, that Vimentin negatively regulates HCV core 
protein levels and HCV production [228] suggesting that modulation of hepatic Vimentin 
expression may critically influence the outcome of an HCV infection. As mentioned 
above no antibody is available for detection of mutated HCV core protein, meaning that 
this hypothesis could not be investigated in this study.  
Several investigations consistently found that overexpression of HCV core protein in 
hepatoma cells results in an upregulation of TGF-β1 protein by activation of MAPK 
signaling pathways [121] [122] [123]. An upregulation of TGF-β could not be confirmed 
in this study. However, the expression of CTGF, a downstream target of TGF-β, was 
highly upregulated in Huh7-HCV core cells, independent of exogenous TGF-β treatment. 
In contrast, Nagaraja et al. 2012 reported recently, that CTGF upregulation in Huh7.5 
cells is dependent on TGF-β through sequential activation of MAP kinase and Smad 
dependent pathways [229]. Similarly, Shin et al published, that overexpression of HCV 
core protein promotes liver fibrogenesis via upregulation of CTGF and TGF-β1 in HepG2 
cells co-cultured with HSCs [122]. CTGF has been linked to TGF-β pathways in fibro-
proliferative diseases before [230]. In regard to this, the role of CTGF upregulation and 
its suitability for the assessment of liver fibrosis in HCV infected patients was 
investigated by Kovalenk et al. 2009. It was shown that HCV infected patients had 
significantly higher serum CTGF levels than healthy controls and that CTGF correlated 
with the histological degree of liver fibrosis [126]. Overall these data suggest that 
infection with HCV is associated with an upregulation of CTGF expression.  
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However, results obtained in this study which are related to the impact of TGF-β in this 
process are in contrast to results of current literature. This might be due to the different 
investigational cell models used. In sum, this study shows the ability of the HCV core 
protein to activate cell survival, while inhibiting apoptotic pathways; it interferes with 
inhibitors of cell cycle progression, while inducing expression of mitogenic factors, which 
promote proliferation and migration. Taken together, data obtained in this study suggest 
that HCV core protein modulates the TGF-β signaling pathway. In Huh7-HCV core cells, 
reduced Smad3 activity resulted in decreased TGF-β induced cell death, indicating that 
virus infection provides the escape of neoplastic hepatocytes from the TGF-β cytostatic 
response, thereby facilitating cancer progression. However, no indices of the induction 
of tumor promoting TGF-β effects like EMT and migration in dependency of TGF-β and 
HCV core protein could be shown. Instead, downstream signaling promoting 
fibrogenesis and tumorigenesis, like enhanced proliferation and migration, increased 
Vimentin and CTGF expression, was induced by HCV core protein expression and 
independent of TGF-β. 
 
5.2.2 Interference of HCV with TGF-β signaling 
Overexpression of HCV core protein in Huh7 cells revealed impaired Smad3 
phosphorylation and transcriptional activity. To investigate these results in a model with 
full HCV, Huh7.5 cells sensitive for full HCV replication, were used. Huh7.5 cells were 
electroporated with HCV RNA and treated with TGF-β. HCV replication levels were 
equal between the different experiments, and TGF-β treatment had no impact on HCV 
replication. Immunoblot analysis of Smad phosphorylation levels upon TGF-β treatment 
in Huh7.5 cells revealed no difference between different experiments conducted. CAGA 
reporter activity assay revealed no changes upon TGF-β treatment in HCV infected or 
uninfected cells. Rapid development of quasispecies due to the high error rate of the 
RNA-Polymerase is one reason why HCV replication in vitro is not stable for longer 
periods. Thus, Huh7.5 cells might be suitable for investigations of HCV replication on 
either one hand, but on the other hand probably display a rather unstable model for 
investigations of cell signaling events. In general, these results show that elucidation of 
HCV induced HCC in cell culture models remain difficult; the development of 
quasispecies, the high cell death rate induced by the rapid depletion of cellular 
resources due to the high replication rate, and the safety issues, hamper this research. 
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